Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Lung Cancer

Aliases
Lung Carcinoma, Lung Neoplasms, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer (1 other aliases)

816 clinical trials

807 products

78 drugs

Clinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
Zimberelimab
Product
Carboplatin
Product
Pemetrexed
Product
Pembrolizumab
Product
Etrumadenant
Product
TNG260
Clinical trial
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-07-01
Product
MGY825
Product
Lorlatinib
Clinical trial
Lorlatinib in Patients With Advanced Non-Small Cell Lung Cancer Who Progress on First- and Second- Generation Tyrosine Kinase Inhibitor: A Real-world Evidence Among Taiwanese Population, Non-Interventional Study
Status: Completed, Estimated PCD: 2021-01-18
Product
177Lu-RAD204
Clinical trial
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)
Status: Active (not recruiting), Estimated PCD: 2023-01-24
Clinical trial
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Gotistobart
Product
Docetaxel
Clinical trial
A Randomized, Open-Label, Multicenter, Phase 2, Umbrella Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations With and Without Chemotherapy as Neoadjuvant Treatment in Chinese Patients With Resectable Stage II to IIIA Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Ociperlimab
Product
LBL-007
Product
Tislelizumab
Product
Cisplatin
Product
Paclitaxel
Clinical trial
An Open-label, Phase I, Dose Escalation, Expansion Study of MGY825 in Adult Patients With Advanced Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-08-17
Clinical trial
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
Status: Terminated, Estimated PCD: 2023-02-13
Product
NIR178
Clinical trial
A Clinical Study of 35 kDa Hyaluronan Fragment in Treatment of Pain and Discomfort Associated With Advanced Lung Cancer
Status: Completed, Estimated PCD: 2023-11-01
Product
35 kDa hyaluronan fragment
Product
PDR001
Clinical trial
A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI4736) in Participants With Advanced Solid Tumours.
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Product
NGM831
Clinical trial
A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Product
NGM831 and NGM438 plus pembrolizumab
Product
Lenvatinib
Clinical trial
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)
Status: Active (not recruiting), Estimated PCD: 2021-05-19
Product
AZD8701
Product
Durvalumab
Clinical trial
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2024-12-01
Product
CDX-585
Product
capmatinib
Product
Placebo
Clinical trial
A PHASE 1B, 12-WEEK, OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF PF-06946860 IN PATIENTS WITH CANCER AND CACHEXIA
Status: Completed, Estimated PCD: 2022-03-30
Clinical trial
Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants With Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification (Geometry-N)
Status: Active (not recruiting), Estimated PCD: 2026-08-06
Product
PF-06946860
Clinical trial
Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Status: Active (not recruiting), Estimated PCD: 2024-08-23
Clinical trial
A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Fludarabine
Product
Tebotelimab
Clinical trial
A Phase Ib/II Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Status: Recruiting, Estimated PCD: 2028-08-01
Product
Ribociclib
Clinical trial
KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Status: Recruiting, Estimated PCD: 2027-05-05
Clinical trial
An Open-Label Study of GV20-0251 in Patients With Advanced and/or Refractory Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-12-15
Clinical trial
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
Status: Completed, Estimated PCD: 2023-02-08
Product
MDX2001
Clinical trial
An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
cetuximab
Clinical trial
A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-08-01
Clinical trial
A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
CRX100
Product
Cyclophosphamide
Clinical trial
A Phase 1 Study of TAS2940 in Patients With Locally Advanced or Metastatic Solid Tumors With EGFR and / or HER2 Aberrations
Status: Recruiting, Estimated PCD: 2025-05-01
Product
CCS1477
Clinical trial
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.
Status: Recruiting, Estimated PCD: 2024-03-01
Product
Enzalutamide
Product
Darolutamide
Product
Atezolizumab
Product
Sacituzumab Govitecan-hziy
Product
Abiraterone
Clinical trial
A Phase Ib Study to Evaluate the Efficacy and Safety of RC48-ADC for Injection in Subjects With Advanced Non-small Cell Lung Cancer With HER2 Overexpression or HER2 Mutation
Status: Completed, Estimated PCD: 2021-12-21
Product
TAS2940
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-04-01
Product
RC48
Clinical trial
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2022-09-13
Clinical trial
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Status: Terminated, Estimated PCD: 2023-12-01
Product
E-602
Clinical trial
A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.
Status: Recruiting, Estimated PCD: 2025-04-30
Product
BT-001
Product
Abemaciclib
Clinical trial
A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2020-02-03
Product
Anastrozole
Clinical trial
Explore the Relationship Between Single Nucleotide Polymorphisms and Alectinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer.
Status: Not yet recruiting, Estimated PCD: 2024-11-18
Product
SKB264
Product
KL-A167
Clinical trial
A Phase Ⅱ Clinical Study of Combination Therapy of SKB264 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-08-01
Product
M7824
Clinical trial
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2021-06-07
Clinical trial
A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Anti-PD-1-Resistant Locally Advanced or Metastatic Cancers
Status: Not yet recruiting, Estimated PCD: 2027-12-31
Product
Alintegimod
Clinical trial
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2023-02-17
Clinical trial
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Status: Terminated, Estimated PCD: 2021-01-15
Product
Alectinib
Clinical trial
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
Status: Recruiting, Estimated PCD: 2024-07-01
Product
CTX-8371
Product
BBP-398
Product
FOG-001
Clinical trial
A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC)
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers
Status: Recruiting, Estimated PCD: 2025-06-01
Product
BMF-219
Product
margetuximab
Product
Telisotuzumab
Product
Ipilimumab
Product
Nivolumab
Product
OSE2101
Product
Necitumumab
Product
Gemcitabine
Clinical trial
A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2013-06-17
Clinical trial
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-10-06
Product
89Zr-DFO-girentuximab
Clinical trial
An Open-label, Dose-escalation, Phase 1 Study to Investigate the Safety and Tolerability of WM-A1-3389, in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-02-22
Clinical trial
A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2026-03-01
Product
CDX-1140
Product
Olaparib
Product
SEA-TGT
Clinical trial
Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX
Status: Recruiting, Estimated PCD: 2025-12-08
Product
WM-A1-3389
Product
GV20-0251
Clinical trial
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
Status: Recruiting, Estimated PCD: 2024-06-01
Product
sotorasib
Product
JDQ443
Product
trametinib
Product
Tovorafenib
Product
BLU-451
Clinical trial
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations
Status: Recruiting, Estimated PCD: 2025-07-31
Product
BDTX-1535
Product
CBX-12
Product
CDX-301
Product
NGM831 plus Pembrolizumab
Product
Chemotherapy
Product
Pimasertib
Product
pembrolizumab
Product
BDC-3042
Product
XNW5004
Product
sasanlimab
Product
Brentuximab vedotin
Product
Etoposide
Clinical trial
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients With EGFR Mutant Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Product
Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab
Product
Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed
Product
AB122
Clinical trial
Platform Study of AB122 Based Treatments in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-05-01
Product
TAS-116
Product
cyclophosphamide
Clinical trial
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
Status: Active (not recruiting), Estimated PCD: 2028-11-02
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
Status: Active (not recruiting), Estimated PCD: 2021-08-09
Product
Taletrectinib
Product
osimertinib
Product
ONC-392
Product
canakinumab
Product
DZD9008+AZD4205
Product
Canakinumab
Product
carboplatin
Product
paclitaxel
Clinical trial
A Phase II, Multicenter Study to Assess the Safety, Tolerability and Anti-tumor Efficacy of DZD9008 in Combination With AZD4205 in Standard Treatment Failed Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Mutations
Status: Recruiting, Estimated PCD: 2025-06-01
Product
cisplatin
Clinical trial
A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-11-09
Product
nivolumab
Product
ipilimumab
Clinical trial
A Phase 1/2, Randomized Study Evaluating Multiple Nivolumab Combination Therapies in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy and Anti-PD-1 (L)1 Immunotherapy
Status: Withdrawn, Estimated PCD: 2023-12-17
Product
docetaxel
Product
lucitanib
Product
gavo-cel
Product
fludarabine
Clinical trial
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase I Tolerance, Safety and Efficacy Study of Alkotinib in Patients With Advanced ALK Positive /ROS1 Positive NSCLC and Previously Treated With Chemotherapy or Crizotinib
Status: Completed, Estimated PCD: 2022-10-17
Product
CX-2029
Clinical trial
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Status: Recruiting, Estimated PCD: 2024-06-30
Product
MEM-288
Clinical trial
A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)
Status: Completed, Estimated PCD: 2023-06-01
Product
Efineptakin alfa
Clinical trial
A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
nab-paclitaxel
Product
pemetrexed
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy and Safety of Neoadjuvant Treatment With Tislelizumab (BGB-A317, Anti-PD-1 Antibody) or Placebo Plus Platinum-Based Doublet Chemotherapy Followed By Adjuvant Tislelizumab or Placebo in Resectable Stage II or IIIA Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Product
AMG 160
Product
Cemiplimab
Product
Placebos
Clinical trial
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2021-12-08
Product
NM21-1480
Clinical trial
A Two-Part, Phase 1b/2, Multicenter, Open-Label, Dose Escalation and Double-Blind, Randomized, Placebo-Controlled, Dose Expansion Study of the Safety, Efficacy and Pharmacokinetics of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Subjects With Locally Advanced and Metastatic Non-Small Cell Lung Cancer
Status: Withdrawn, Estimated PCD: 2025-06-01
Clinical trial
A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2024-02-06
Product
cabozantinib
Product
ramucirumab
Product
Naptumomab estafenatox
Product
Obinutuzumab
Product
TAS-120
Product
Ramucirumab
Clinical trial
Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2024-01-30
Product
NIZ985
Product
Spartalizumab
Clinical trial
Phase I Study of MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2025-11-01
Product
TAS-115
Product
TAS-102
Clinical trial
A Phase 1, Open-Label, Multicenter, Drug-Drug Interaction Study of TAK-788 and Midazolam, a Sensitive CYP3A Substrate, in Patients With Advanced Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2020-12-17
Product
TAK-788
Product
Domvanalimab
Clinical trial
A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU-201, a B-Cell Immunotherapy as Monotherapy or in Combination With Atezolizumab With or Without Chemotherapy, in Adults With Non- Small Cell Lung Cancer (IMPrinter)
Status: Active (not recruiting), Estimated PCD: 2026-02-01
Product
Midazolam
Product
NGM438
Clinical trial
A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL-15/sIL-15Rα)) in Combination With Spartalizumab in Patients With Check Point Inhibitor (CPI) Relapsed Advanced Solid Tumors and Lymphoma
Status: Terminated, Estimated PCD: 2023-12-27
Product
Alkotinib
Product
MRTX0902
Product
MRTX849
Clinical trial
A Multicenter, Open-label, Phase 1a/b Study of HC-7366 in Subjects With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2024-02-09
Product
HC-7366
Clinical trial
A Multicentre, Phase II, Single-Arm, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy (CT), Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy (CRT) and Consolidation Durvalumab, in Participants With Resectable or Borderline Resectable Stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation
Status: Recruiting, Estimated PCD: 2025-08-30
Product
Immune checkpoint blockers
Product
IMU-201
Product
Vebreltinib
Clinical trial
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Chemotherapy in the Treatment of EGFR WT and ALK WT Recurrent and Metastatic Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-04-01
Product
AP or TP
Clinical trial
A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway
Status: Recruiting, Estimated PCD: 2026-06-30
Product
DK210
Product
SI-B001
Clinical trial
A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of MB1707 in Patients With Advanced Cancer
Status: Withdrawn, Estimated PCD: 2024-11-01
Clinical trial
Treatment Plan of the HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Status:
Product
MCLA-128
Product
MB1707
Product
NT-112
Clinical trial
A Phase Ib/II Study of Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Status: Completed, Estimated PCD: 2023-08-29
Product
Avutometinib
Clinical trial
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Status: Active (not recruiting), Estimated PCD: 2028-10-30
Product
TC-510
Product
Standard of care chemotherapy
Product
PLB1004
Product
Navtemadlin
Product
N-803 + Pembrolizumab
Product
N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab
Product
N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed
Product
BLU-945
Product
Niraparib
Clinical trial
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 Mutations
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects With Advanced Solid Tumors Including a Dose-escalation Safety Study (Part 1) and Preliminary Efficacy Assessment of DSP107 as Monotherapy and in Combination With Atezolizumab (Part 2)
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
An Open-Label, Multicenter, Phase 1 Study With Expansion Cohorts of Ramucirumab or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI Therapy
Status: Completed, Estimated PCD: 2017-10-19
Clinical trial
A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor.
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults With Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-08-01
Product
LYL845
Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY AND PHARMACODYNAMICS OF PF-07263689, EITHER ALONE OR IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY, IN PREVIOUSLY TREATED PARTICIPANTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Status: Terminated, Estimated PCD: 2022-10-14
Product
CAB-AXL-ADC
Product
PD-1 inhibitor
Product
DSP107
Clinical trial
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Status: Active (not recruiting), Estimated PCD: 2020-02-26
Clinical trial
A Multi-centered, Randomized, Open-label Phase III Study to Evaluate the Efficacy and Safety of TGRX-326 Comparing With Crizotinib in Patients of Advanced ALK-positive or Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Product
ABT-101
Product
ponsegromab
Clinical trial
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)
Status: Active (not recruiting), Estimated PCD: 2024-03-13
Product
TGRX-326
Product
Crizotinib
Clinical trial
A Phase Ib/II, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ABT-101 in Patients With Advanced Solid Tumors and HER2 Exon 20 Insertions Mutated Non- Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-11-01
Product
TSR-042
Product
Carboplatin-Paclitaxel
Product
Bevacizumab
Product
TSR-022
Product
Carboplatin-Pemetrexed
Product
Carboplatin-Nab-Paclitaxel
Product
BBI-355
Product
PF-07263689
Product
Sasanlimab
Product
DZD9008 + Bevacizumab
Clinical trial
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-01
Product
LYL797
Product
STK-012
Clinical trial
A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-03-01
Product
BI 836880
Clinical trial
An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With Ezabenlimab to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer and in Other Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-06
Product
ezabenlimab
Clinical trial
A Phase II, Single Arm, Multicenter Study to Assess the Safety, Tolerability and Anti-Tumor Efficacy of DZD9008 With Bevacizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutations (WU-KONG29)
Status: Recruiting, Estimated PCD: 2025-05-31
Product
Placebo for osimertinib
Product
Erlotinib
Clinical trial
A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Versus Durvalumab in Patients With Locally Advanced, Unresectable, PD-L1-Selected Non-Small Cell Lung Cancer Whose Disease Has Not Progressed After Concurrent Chemoradiotherapy
Status: Terminated, Estimated PCD: 2023-10-17
Product
Futibatinib
Product
AP
Product
Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab
Product
Cisplatin + Pembrolizumab + Pemetrexed
Clinical trial
A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF-06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA, FOLLOWED BY AN 18-WEEK OPEN-LABEL TREATMENT PERIOD
Status: Completed, Estimated PCD: 2022-04-14
Product
Osimertinib
Product
PF-06946860 Placebo
Product
Ponsegromab
Product
35 kDa Hyaluronan Fragment
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients With EGFRm, Locally Advanced or Metastatic NSCLC Who Have Progressed Extracranially Following First-Line Osimertinib Therapy (COMPEL)
Status: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
Status: Recruiting, Estimated PCD: 2024-10-01
Product
DO-2
Product
Vobramitamab
Clinical trial
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-03-18
Clinical trial
A Phase 1 Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-31
Product
SGN-BB228
Product
Brentuximab Vedotin
Product
THOR-707
Product
NAP
Product
ELI-002
Clinical trial
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-01-26
Product
Carboplatin + Nab-paclitaxel + Pembrolizumab
Clinical trial
An Open Label, Multicenter, Dose Escalation, Phase 1 Study to Evaluate Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti Tumor Activity of RO7247669, a PD1-LAG3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
INCB086550
Clinical trial
A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2023-07-18
Product
SO-C101
Clinical trial
An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7515629 in Participants With Unresectable and/or Metastatic HLA-G Positive Solid Tumors
Status: Terminated, Estimated PCD: 2024-03-19
Product
RO7515629
Clinical trial
A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy
Status: Recruiting, Estimated PCD: 2024-12-31
Product
tocilizumab
Product
CLN-081
Product
RO7247669
Clinical trial
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)
Status: Completed, Estimated PCD: 2021-10-18
Product
A2B694
Clinical trial
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Status: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530, an Autologous Logic-gated Tmod™ Chimeric Antigen Receptor T Cell (CAR T), in Heterozygous HLA-A*02 Adult Subjects With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
Status: Recruiting, Estimated PCD: 2026-12-01
Product
A2B530
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of QLC1101 Monotherapy in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Status: Recruiting, Estimated PCD: 2026-05-31
Product
QLC1101
Clinical trial
An Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-11-05
Product
Keytruda
Product
DS-1062a
Product
NT-I7
Clinical trial
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2028-05-01
Product
MGC026
Clinical trial
Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum Based Chemotherapy (TROPION-Lung05)
Status: Active (not recruiting), Estimated PCD: 2023-03-10
Clinical trial
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor-Naïve With Selected Solid Tumors
Status: Terminated, Estimated PCD: 2024-03-26
Product
IPH5201 + Durvalumab + Standard Chemotherapy
Clinical trial
Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE)
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Vobramitamab Duocarmazine
Clinical trial
A Dose Escalation and Expansion Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-326 Monotherapy for the Treatment of Advanced ALK-positive or ROS1-positive Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-08-31
Clinical trial
Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01)
Status: Active (not recruiting), Estimated PCD: 2024-05-10
Product
Allogeneic NK
Clinical trial
Phase 1-2 Trial of Systemically Administered VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Selected Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Ipilimumab + Nivolumab
Product
VSV-IFNβ-NIS
Clinical trial
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
Status: Withdrawn, Estimated PCD: 2025-06-30
Product
FMC-376
Clinical trial
An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2027-10-01
Clinical trial
A First-in-Human (FiH) Study of IK-595, an Oral Dual MEK/RAF Inhibitor, in Patients With RAS-or RAF-altered Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2027-05-01
Product
IK-595
Clinical trial
A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Simvastatin (a Sensitive CYP3A4 Substrate) in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI
Status: Active (not recruiting), Estimated PCD: 2015-04-30
Product
AZD9291
Product
TOS-358
Product
Simvastatin
Clinical trial
A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Status: Recruiting, Estimated PCD: 2024-09-01
Drug
Atezolizumab
Product
Tabrecta
Clinical trial
Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced/Recurrent Non-small Cell Lung Cancer)
Status: Recruiting, Estimated PCD: 2024-10-31
Product
MT-8421
Clinical trial
A Phase 1b/2 Study of BMS-986442 in Combination With Nivolumab or Nivolumab and Chemotherapies in Participants With Advanced Solid Tumors and Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2026-11-01
Product
Pemexetred
Clinical trial
A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemotherapy
Status: Completed, Estimated PCD: 2023-03-30
Product
BMS-986442
Clinical trial
An Open-label, Prospective, Multi-center, Single-arm Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in Non-small Cell Lung Cancer (NSCLC) With Uncommon Epidermal Growth Factor Receptor Mutations (EGFRm)
Status: Recruiting, Estimated PCD: 2029-06-30
Clinical trial
NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-12-30
Product
Entrectinib
Product
Cobimetinib
Product
Pralsetinib
Product
Divarasib
Product
Vemurafenib
Product
SBRT
Product
INBRX-105
Product
N-803
Product
JK08
Clinical trial
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients With Unresectable Locally Advanced or Metastatic Cancer
Status: Recruiting, Estimated PCD: 2025-10-17
Clinical trial
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2017-09-15
Product
Lenvatinib + Envafolimab
Clinical trial
Envafolimab(KN035) in Combination With Lenvatinib in the Treatment of Advanced Solid Tumors: a Multicenter, Open-label, Phase Ib/II Study
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 / 2 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Sunitinib
Clinical trial
International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastin® (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) Patients
Status: Completed, Estimated PCD: 2014-11-01
Product
Sutetinib Maleate
Clinical trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS
Status: Recruiting, Estimated PCD: 2027-07-29
Clinical trial
A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
Status: Completed, Estimated PCD: 2023-01-17
Product
Saline
Product
PF-07799933
Product
binimetinib
Clinical trial
A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Status: Recruiting, Estimated PCD: 2027-01-08
Product
TNO155
Product
ANK-101
Clinical trial
A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Naïve Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2019-06-30
Product
BDTX-4933
Product
Tiragolumab
Clinical trial
A Prospective, Multicenter, Open-label, Phase IV, Interventional Study to Assess the Safety and Efficacy of Capmatinib in Indian Patients With Mesenchymalepithelial Transition (MET) Exon 14 Skipping Mutation Positive Advanced Nonsmall Cell Lung Cancer (NSCLC).
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
Status: Recruiting, Estimated PCD: 2027-09-01
Product
Nab-paclitaxel
Product
MK-1084
Clinical trial
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Phase 1, Open-label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms
Status: Recruiting, Estimated PCD: 2026-06-01
Product
Itraconazole+TGRX-326
Product
Efavirenz+TGRX-326
Clinical trial
A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1 TPS ≥50%
Status: Recruiting, Estimated PCD: 2029-02-19
Product
SNS-101
Product
tislelizumab
Clinical trial
A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Product
Capmatinib
Clinical trial
An Open-label, Two-cycle, Single Sequence, Self-controlled Study Evaluating Effects of Oral Itraconazole or Efavirenz on Pharmacokinetic Profiles of TGRX-326
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels
Status: Recruiting, Estimated PCD: 2030-01-16
Product
fianlimab
Product
cemiplimab
Product
Tomivosertib
Clinical trial
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Product
crizotinib
Clinical trial
A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2026-12-30
Clinical trial
A Phase 1a/1b Open-Label Study of BBO-8520 Monotherapy and BBO-8520 in Combination With Pembrolizumab in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - the ONKORAS-101 Study
Status: Recruiting, Estimated PCD: 2027-08-01
Product
X-396
Product
FPI-2053
Product
[111In]-FPI-2107
Product
[225Ac]-FPI-2068
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Status: Active (not recruiting), Estimated PCD: 2024-10-14
Product
BBO-8520
Clinical trial
A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2019-09-23
Clinical trial
A Phase 1, Multicentre, Open-label, Nonrandomised, First-in-human Study of OVM-200 as a Therapeutic Vaccine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Ovarian Cancer, and Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2024-02-22
Product
INCB106385
Product
INCMGA00012
Product
MSC-1
Product
OVM-200
Clinical trial
A Phase 1/2, Open-label, Dose-escalation, and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101 as a Single Agent and in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Patients With Advanced or Metastatic Solid Tumors (Keynote B59)
Status: Recruiting, Estimated PCD: 2025-10-01
Product
GI-101
Product
GI-101A
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2030-06-25
Product
NGM831 plus pembrolizumab
Product
NGM831 and NGM438 plus Pembrolizumab
Clinical trial
Phase I/II First-in-Human Study of TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-05-14
Product
TT-10
Product
dabrafenib
Clinical trial
Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
Status: Recruiting, Estimated PCD: 2027-12-20
Product
ATSN-101
Clinical trial
A Phase 1/2 Dose Escalation Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Status: Active (not recruiting), Estimated PCD: 2023-05-19
Product
Prednisone
Product
Triamcinalone Acetonide
Product
BL-M07D1
Clinical trial
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2 Mutated, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Product
Telisotuzumab Vedotin
Clinical trial
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-06-07
Clinical trial
Positioning, Utilization and Effectiveness of Osimertinib in First Line in Real-life Therapeutic Strategy in France Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
Status: Active (not recruiting), Estimated PCD: 2026-01-15
Product
Immunotherapy
Clinical trial
ARGONAUT: Development and Analysis of a Blood and Stool Sample Bank for Cancer Patients, Enabling the Systematic Study of the Effect of Gut Microbiomes on Response to Treatment
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
Status: Recruiting, Estimated PCD: 2025-12-30
Product
CTX-471
Product
CAB-ROR2-ADC
Clinical trial
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-08-05
Product
KY1044
Product
KY1044 and Atezolizumab
Clinical trial
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients With Select Relapsed Advanced Malignancies (JIVAN)
Status: Recruiting, Estimated PCD: 2025-05-01
Product
Prednisolone
Product
Trimethoprim + Polymyxin B
Clinical trial
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2026-07-06
Product
V940
Product
AUR106
Clinical trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF PF-07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Status: Terminated, Estimated PCD: 2023-10-16
Product
HFB200301
Product
PRO1107
Clinical trial
A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-02-01
Product
DZD9008 plus Bevacizumab
Clinical trial
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2029-08-09
Product
LN-145-S1
Product
Lifileucel
Product
LN-145
Product
GT201
Clinical trial
A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Product
PF-07265028
Product
BAY2862789
Clinical trial
A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT201 Injection ) in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Alpha Inhibitor (DGKαi) BAY 2862789 in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-17
Clinical trial
A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of H002 in Patients With Active EGFR Mutation Locally Advanced or Metastatic NSCLC
Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Status: Terminated, Estimated PCD: 2024-01-30
Product
Triamcinalone
Product
NGM831 + Pembrolizumab
Product
NC762
Product
H002
Product
RO7496353
Clinical trial
A Phase Ib, Open-Label, Multicenter Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-30
Product
Capecitabine
Product
S-1
Product
Oxaliplatin
Clinical trial
A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)
Status: Recruiting, Estimated PCD: 2028-12-22
Product
Dato-DXd
Product
Pemetrexed/Cisplatin
Product
Oleclumab
Product
Monalizumab
Product
AZD0171
Product
Pemetrexed/Carboplatin
Product
Carboplatin/Paclitaxel
Product
Volrustomig
Clinical trial
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Status: Terminated, Estimated PCD: 2023-11-28
Product
Ladiratuzumab vedotin
Product
AK105
Clinical trial
A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Paclitaxel vs Placebo Combined With Carboplatin and Paclitaxel as First-line Therapy in Patients With Metastatic Squamous Non-small Cell Lung Cancer
Status: Completed, Estimated PCD: 2020-10-08
Product
BI-1910
Clinical trial
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-07-14
Product
AZD5305
Clinical trial
A Phase 1/2a Study of IMM-6-415 in Participants With Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations
Status: Recruiting, Estimated PCD: 2027-06-01
Product
IMM-6-415
Clinical trial
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2026-12-15
Product
T- Dxd
Product
Camizestrant
Clinical trial
A Phase 1/1b Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors.
Status: Terminated, Estimated PCD: 2024-01-15
Product
SAR443216
Clinical trial
Phase 2, Open-Label Study in Subjects With Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2025-03-18
Clinical trial
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-02-01
Product
XL092
Clinical trial
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of PT199 Administered Alone and in Combination With a PD-1 Inhibitor in Adult Patients With Advanced Solid Tumors.
Status: Recruiting, Estimated PCD: 2024-12-01
Product
BL-B01D1
Clinical trial
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2025-11-01
Product
SI-B003
Product
encorafenib
Clinical trial
A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2022-09-22
Product
GT201 + Teraplizumab
Product
PT199
Clinical trial
A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-30
Product
Nivolumab + Relatlimab
Product
OBX-115
Product
Placebo for Osimertinib
Product
CISH Inactivated TIL
Product
Aldesleukin
Clinical trial
Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3)
Status: Completed, Estimated PCD: 2023-02-22
Clinical trial
A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase I/Ib Study to Evaluate the Safety, Tolerability, Biological and Clinical Activities of GEN-001 in Combination With Avelumab in Patients With Advanced Solid Tumors Who Have Progressed During or After Treatment With Anti-PD-(L)1 Therapy
Status: Completed, Estimated PCD: 2023-01-11
Product
PLB1001
Product
AraG
Product
ONM-100
Clinical trial
Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
TPST-1495
Product
CM-24 and Nivolumab
Product
CM-24
Clinical trial
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Nivolumab, Nab paclitaxel and Gemcitabine
Product
Nivolumab and Nal-IRI/5-FU/LV
Clinical trial
A Multi-center, Open-label, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CTS2190 in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-31
Product
CTS2190
Product
Avutometinib + Adagrasib
Clinical trial
A Multi-centered, Open-label, Single-arm Phase II Study to Evaluate the Safety and Efficacy of TGRX-326 Monotherapy in Patients of Advanced ALK-positiveNon-Small Cell Lung Cancer Who Failed 2nd-Generation ALK Inhibitor Therapies
Status: Recruiting, Estimated PCD: 2024-02-28
Product
RC198
Product
Datopotamab Deruxtecan
Clinical trial
A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2028-03-21
Clinical trial
Phase I Study of TTI-101, an Oral Inhibitor of Signal Transducer and Activator of Transcription (STAT) 3, in Patients With Advanced Cancers
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
TTI-101
Product
Adagrasib
Clinical trial
A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Status: Recruiting, Estimated PCD: 2026-02-28
Product
Pemetrexed+carboplatin
Clinical trial
A Phase 1/2 Trial (CheckCell-2) in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Randomized, Open-label, Single-dose, 3-cycle, 6-sequence, Crossover Study Evaluating Food Effect on Pharmacokinetic Profiles of TGRX-326 in Chinese Healthy Subjects and Effect of Drug Specification on Bioavailability in Human
Status: Completed, Estimated PCD: 2024-01-12
Product
Cycle 2
Product
Cycle 3
Product
Cycle 1: Treatment Drug
Product
Cycle 1
Product
GEN-001
Product
Avelumab
Clinical trial
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
Status: Recruiting, Estimated PCD: 2025-10-31
Product
HS-10296
Product
Gefitinib
Product
BMC128
Clinical trial
A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of BMC128 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer (NSCLC), Melanoma or Renal Cell Carcinoma (RCC)
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Acasunlimab
Product
IPH5201 + Durvalumab
Product
ACY-241
Clinical trial
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
Status: Recruiting, Estimated PCD: 2024-03-01
Product
KIN-2787
Clinical trial
A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Nivolumab in Patients With Unresectable Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2024-01-22
Product
Neoantigen specific TCR-T cell
Clinical trial
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen
Status: Completed, Estimated PCD: 2020-08-10
Clinical trial
A First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Product
TUB-040
Clinical trial
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)
Status: Completed, Estimated PCD: 2018-09-04
Clinical trial
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Adagrasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)
Status: Recruiting, Estimated PCD: 2024-07-24
Clinical trial
A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care EGFR TKI, as First Line Treatment to EGFR Mutation Positive Advanced NSCLC With CNS Metastases
Status: Completed, Estimated PCD: 2022-07-12
Clinical trial
An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 1, Open Label, Dose Escalation of HBI-2438 in Patients With Advanced Malignant Solid Tumors Harboring KRAS G12C Mutation
Status: Recruiting, Estimated PCD: 2025-08-01
Product
HBI-2438
Product
DZD9008
Clinical trial
A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2018-06-22
Clinical trial
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Using the Sleeping Beauty System to Express T Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors
Status: Recruiting, Estimated PCD: 2039-04-01
Clinical trial
A Retrospective Observational, Multi-Centre, Cohort Study to Understand Real-World Treatment Patterns and Clinical Outcomes of Adult Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada
Status: Completed, Estimated PCD: 2022-08-31
Product
AZD3759
Clinical trial
Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
TPX-0131
Product
CVA21/pembrolizumab
Clinical trial
A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC
Status: Terminated, Estimated PCD: 2023-04-18
Product
AB248
Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
JAB-3312
Clinical trial
An Open-Label, Multicenter, Phase 1b/2 Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2022-07-29
Clinical trial
Efficacy and Safety of First-line mil60 Plus Paclitaxel/Carboplatin Versus Bevacizumab Plus Paclitaxel/Carboplatin in Patients With Advanced and Recurrent Non-squamous Non-small Cell Lung Cancer: a Randomized, Double-blind, Phase 3 Study
Status: Completed, Estimated PCD: 2019-08-01
Product
GLR2007
Clinical trial
An Open-label PET Study to Determine Brain Exposure of Osimertinib After IV Microdose Administration of [11C]Osimertinib and Therapeutic Oral Doses of Osimertinib to Patients With EGFR Mutated NSCLC With Brain Metastases
Status: Completed, Estimated PCD: 2020-03-19
Product
[11C]osimertinib
Clinical trial
A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)
Status: Terminated, Estimated PCD: 2022-04-20
Clinical trial
Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1 Directed Therapy
Status: Recruiting, Estimated PCD: 2024-10-15
Clinical trial
A Phase III Randomized, Controlled, Double-Blind, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of HS-10296 Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic NSCLC With EGFR Sensitizing Mutations
Status: Active (not recruiting), Estimated PCD: 2021-01-15
Product
ADCT-301
Clinical trial
A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2023-12-01
Product
Saline placebo
Product
QLH11811
Product
Anamorelin
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2022-07-04
Product
WX-0593
Clinical trial
A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC
Status: Recruiting, Estimated PCD: 2025-04-22
Clinical trial
Phase I Clinical Study of Chimeric Antigen Receptor T Cells (C-13-60) in the Treatment of Carcinoembryonic Antigen (CEA) Positive Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase 1, Open-label, Non-Randomized Study to Assess the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients With EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-08-19
Clinical trial
Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors
Status: Recruiting, Estimated PCD: 2024-01-01
Product
TQB3728
Clinical trial
A Randomized, Open Label, Parallel Controlled, Multicenter Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.
Status: Not yet recruiting, Estimated PCD: 2024-09-01
Product
TQB2450
Clinical trial
An Open, Multi-center, Single-arm Phase IIIb Confirmatory Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Vebreltinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Exon 14 Mutation
Status: Active (not recruiting), Estimated PCD: 2026-09-30
Product
Recombinant oncolytic herpes simplex virus type 1 (R130)
Product
CAN04
Product
RAPA-201
Product
XZP-5809-TT1
Product
EMB-01
Clinical trial
Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of QLH11811 in Advanced or Metastatic NSCLC Patients Who Have Progressed After EGFR-TKI Treatment
Status: Recruiting, Estimated PCD: 2024-12-31
Product
SGN-CD228A
Clinical trial
A Phase II Study to Investigate the Efficacy and Safety of WX-0593 in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Status: Active (not recruiting), Estimated PCD: 2023-07-15
Clinical trial
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety & Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Solid Tumors Undergoing Routine Surgery
Status: Completed, Estimated PCD: 2021-10-14
Clinical trial
A Single-arm, Open-label, and Multicenter Phase Ⅱ Study Designed to Evaluate the Efficacy and Safety of Rulonilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Status: Not yet recruiting, Estimated PCD: 2024-10-25
Product
Chidamide
Product
Envafolimab
Product
Tucidinostat
Clinical trial
A Randomized, Double-blind, Controlled, Multi-center Phase II Clinical Trial of Tucidinostat Combined With Tislelizumab as First-line Treatment for PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2023-10-01
Product
HS-10241
Clinical trial
A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Status: Completed, Estimated PCD: 2021-06-30
Clinical trial
A Single-arm, Open, Multi-center Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Effectiveness of XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI).
Status: Terminated, Estimated PCD: 2021-05-20
Product
DS-1205c
Clinical trial
A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Gefitinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2020-04-22
Clinical trial
A Phase II Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced Non-Small Cell Lung Cancer(NSCLC).
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase Ib Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC.
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors
Status: Recruiting, Estimated PCD: 2024-10-15
Clinical trial
A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-03-09
Product
F520
Product
IBI308
Product
OTL38
Clinical trial
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Status:
Product
EDP1503
Clinical trial
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)
Status: Completed, Estimated PCD: 2018-09-04
Product
NGM120
Clinical trial
A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
Savolitinib + Osimertinib
Product
Pemetrexed + Cisplatin/Carboplatin
Clinical trial
An Open-label, Randomized, Multicenter Phase 3 Study Comparing WX-0593 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 / 2 Study of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumours
Status: Completed, Estimated PCD: 2023-06-23
Product
NEO-201
Clinical trial
A Phase Ib/II, Open-Label, Multi-Center Study of EMB-01 in Combination With Osimertinib in Patients With Advanced/Metastatic EGFR Mutant Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Completed, Estimated PCD: 2020-01-10
Product
mil60
Product
Selpercatinib
Clinical trial
Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Savolitinib + Osimertinib Versus Pemetrexed + Platinum in Treatment of Patients With NSCLC With MET Amplification
Status: Recruiting, Estimated PCD: 2024-09-15
Clinical trial
A Phase 3, Randomized,Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
Status: Completed, Estimated PCD: 2021-10-07
Product
Platinum Doublet
Clinical trial
A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)
Status: Completed, Estimated PCD: 2018-04-03
Clinical trial
A Phase II/III Clinical Study on the Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Perioperative Treatment of Resectable Stage II/III Non Small Cell Lung Cancer.
Status: Recruiting, Estimated PCD: 2026-06-01
Product
DTX
Clinical trial
A Phase 2, Single Dose, Open-Label, Exploratory Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
Status: Completed, Estimated PCD: 2018-10-31
Product
mFOLFOX
Product
G/C
Clinical trial
A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2022-12-08
Product
TQB2450 + Anlotinib Hydrochloride
Clinical trial
A Phase 1, Multicenter, Open-label, First-in-human Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)
Status: Completed, Estimated PCD: 2020-09-30
Clinical trial
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Immunogenetic and Efficacy of RC198 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-30
Product
YL202
Product
HLX301
Product
CEA-targeted CAR-T cells
Product
Platinum Doublet Chemotherapy
Clinical trial
A Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2023-09-15
Product
Savolitinib
Clinical trial
A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC
Status: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
A Phase Ib/II ,Single Arm, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of JAB-21822 in Advanced or Metastatic Non-small Cell Lung Cancer With a KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Status: Recruiting, Estimated PCD: 2023-12-01
Product
JAB 21822
Clinical trial
A Randomized, Open-Label, Multicenter Phase 3 Study to Evaluate SKB264 Monotherapy Versus Pemetrexed in Combination With Platinum in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy
Status: Recruiting, Estimated PCD: 2025-05-20
Product
AMG 510
Product
MVASI
Clinical trial
A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2022-11-30
Product
ALRN-6924
Clinical trial
A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression
Status: Terminated, Estimated PCD: 2022-07-30
Clinical trial
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis.
Status: Withdrawn, Estimated PCD: 2023-01-31
Clinical trial
A Phase I/II Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors
Status: Terminated, Estimated PCD: 2023-05-08
Product
MRx0518
Clinical trial
A Phase 1 Study of Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JYP0322 in Patients With Locally Advanced/Metastatic Solid Tumors Harboring ROS1 Gene Fusion
Status: Recruiting, Estimated PCD: 2024-06-30
Product
TPX-0046
Clinical trial
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Status: Terminated, Estimated PCD: 2023-05-22
Clinical trial
A Phase I/II, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 in Chinese Patients With EGFRm+ NSCLC With Central Nervous System (CNS) Metastases
Status: Completed, Estimated PCD: 2020-11-13
Product
NGM707
Clinical trial
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Product
HD204
Product
AK112
Clinical trial
An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210(Anti-PD-1 Antibody) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2020-08-20
Product
G1T38
Clinical trial
A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2024-05-28
Clinical trial
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2022-11-10
Product
GRT-R902
Product
Sotorasib
Clinical trial
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX208 （BRAF V600E Inhibitor） Combined With Serplulimab（HLX10, Anti-PD-1 Antibody） in Advanced NSCLC Patients With BRAF V600E Mutation.
Status: Recruiting, Estimated PCD: 2025-03-04
Clinical trial
Retrospective, External Comparator Study to Assess the Real-World Effectiveness of Lazertinib as the Second-Line Treatment Versus Platinum-based Chemotherapy in Patients With EGFR Mutation+ Locally Advanced or Metastatic NSCLC
Status: Completed, Estimated PCD: 2022-04-30
Product
Platinum-based Chemotherapy
Clinical trial
A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES
Status: Terminated, Estimated PCD: 2021-06-07
Product
JYP0322
Product
Relatlimab
Product
Nab-Paclitaxel
Clinical trial
An Open-label, Non-randomised, Phase I Study to Assess the Effect of Single and Multiple Oral Doses of Osimertinib (TAGRISSO™) on the Pharmacokinetics of a P-glycoprotein Probe Drug (Fexofenadine) in Patients With Advanced EGFRm NSCLC That Have Progressed on a Prior EGFR-TKI Regimen
Status: Completed, Estimated PCD: 2017-07-31
Clinical trial
A Phase I Dose-escalation Trial of TG6050 Administered by Intravenous Infusion in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2024-10-30
Product
TG6050
Clinical trial
A Phase Ib/II Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With Advanced NSCLC
Status: Recruiting, Estimated PCD: 2023-05-01
Clinical trial
Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination With Osimertinib in Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2021-12-14
Clinical trial
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Multi-cohort, Randomized, Open, Multicenter Phase II Study to Evaluate the Efficacy and Safety of AL2846 Capsules in Treated Subjects With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Product
SHR-1210
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2022-08-12
Clinical trial
An Observational Study to Assess the Effectiveness and Safety of Cemiplimab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (CEMI-LUNG)
Status: Recruiting, Estimated PCD: 2028-10-27
Product
Lazertinib
Product
Fexofenadine
Clinical trial
A Randomized, Open-Label, Phase 2 Study to Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Product
AL2846
Product
GRT-C901
Product
PRT2527
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation and Confirmation Study of PRT2527 in Participants With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-12-06
Product
TH-4000
Clinical trial
A Phase Ib/IIa, Multicenter, Open-label Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Status: Not yet recruiting, Estimated PCD: 2026-01-25
Product
Toripalimab
Clinical trial
A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2022-12-09
Clinical trial
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study
Status: Recruiting, Estimated PCD: 2024-12-31
Product
AI-061
Product
ILB-2109
Product
RTX-224
Product
SHR-1701+Paclitaxel+carboplatin
Clinical trial
An Open-label, Multicenter Phase II Clinical Trial of SHR-1701 With or Without Chemotherapy in the Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-07-15
Product
Topotecan
Clinical trial
A Phase Ⅱ,Open-label, Single-line, Multiple Cohorts, Multicenter Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
Status: Recruiting, Estimated PCD: 2024-04-30
Product
SHR-1701
Clinical trial
A Randomized, Double-Blind, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin Nanoparticle Albumin Bound (Nab)-Paclitaxel) vs Chemotherapy (Carboplatin Nab-Paclitaxel) as First-Line Therapy for Locally Advanced or Metastatic Squamous Non Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2023-12-30
Product
OBI-833
Clinical trial
An Open-label, Randomized Phase I Study Investigating Safety, Tolerability, Pharmacokinetics, and Efficacy of Pembrolizumab (MK-3475) in Chinese Subjects With Non-Small-Cell Lung Cancer
Status: Completed, Estimated PCD: 2017-09-19
Product
Camrelizumab + Famitinib
Clinical trial
A Randomized, Open-Label, Controlled, Multi-center Phase Ⅲ Study of Camrelizumab Combined With Famitinib Malate Versus Pembrolizumab in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2023-12-31
Product
camrelizumab
Clinical trial
First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-14
Clinical trial
A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor
Status: Terminated, Estimated PCD: 2017-01-01
Product
Aumolertinib
Clinical trial
Efficacy and Safety of Aumolertinib With or Without Chemotherapy as First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing Epidermal Growth Factor Receptor Mutations: A Randomized, Controlled, Open-label, Phase 3 and Multicenter Clinical Study
Status: Recruiting, Estimated PCD: 2024-01-31
Product
HLX10
Product
Carboplatin + Nab Paclitaxel
Clinical trial
A Randomized, Double-blinded, Phase III Study of Pemetrexed Plus Platinum Chemotherapy With or Without Sintilimab (IBI308) in First Line Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (Orient-11)
Status: Completed, Estimated PCD: 2023-02-13
Product
BT5528
Clinical trial
A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies
Status: Completed, Estimated PCD: 2022-04-28
Clinical trial
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer
Status: Completed, Estimated PCD: 2011-04-07
Product
Sintilimab
Product
Platinum
Clinical trial
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
Status: Active (not recruiting), Estimated PCD: 2023-07-10
Clinical trial
A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects With Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-line Treatment (CodeBreaK 201)
Status: Active (not recruiting), Estimated PCD: 2024-11-14
Product
NKTR-214 + Nivolumab + Ipilimumab
Clinical trial
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression
Status: Recruiting, Estimated PCD: 2023-12-31
Product
NGM707 plus Pembrolizumab
Product
BLU-701
Product
NKTR-214 + Nivolumab
Product
HLX208+HLX10
Product
Eribulin Mesylate + Erlotinib
Product
Eribulin + Erlotinib
Clinical trial
Phase II, Open Label, Single-arm Study to Assess Safety and Efficacy of AZD9291 in Patients With Locally Advanced/Metastatic NSCLC Whose Disease Has Progressed With Previous EGFR TKI and Whose Tumours Are EGFR and T790M Mutation Positive
Status: Completed, Estimated PCD: 2015-05-01
Product
AMG 228
Product
Tepotinib
Clinical trial
A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib (MSC2156119J) Combined With Gefitinib Versus Chemotherapy as Second-Line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic NSCLC Harboring EGFR Mutation and Having Acquired Resistance to Prior EGFR-TKI Therapy (INSIGHT)
Status: Completed, Estimated PCD: 2017-12-12
Product
BI 1701963
Product
Tumor-infiltrating lymphocytes
Product
IL-2
Product
RAIN-32
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid Tumors
Status: Terminated, Estimated PCD: 2021-10-12
Clinical trial
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2016-12-12
Clinical trial
A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 1/1b Trial of MRTX849 in Combination With BI 1701963 in Patients With Advanced Solid Tumors With KRAS G12C Mutation
Status: Completed, Estimated PCD: 2022-11-02
Clinical trial
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With EGFR-sensitive Mutations
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Phase I Clinical Trial to Evaluate the Safety and Tolerability of NEOG-100 in Patients With Advanced Breast Cancer and Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC
Status: Active (not recruiting), Estimated PCD: 2021-09-08
Product
Vinorelbine
Clinical trial
A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)
Status: Terminated, Estimated PCD: 2023-10-15
Clinical trial
A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2023-04-06
Product
Ensartinib
Clinical trial
A Phase Ⅲ, Double-blind, Randomized, Placebo-Controlled Multi-centre Study to Assess the Efficacy and Safety of Ensartinib Versus Placebo as Adjuvant Therapy in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Stage Ⅱ- ⅢB Non-small Cell Lung Cancer, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Test-retest Evaluation of [18F]F-AraG PET in Non-small Cell Lung Cancer (NSCLC) Patients
Status: Not yet recruiting, Estimated PCD: 2025-10-31
Product
GEN1029
Product
AG-01
Product
IBI939
Clinical trial
An Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
Status: Completed, Estimated PCD: 2023-01-01
Product
FT536
Product
CDX-527
Clinical trial
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of SI-B001+SI-B003 With or Without Chemotherapy (SI-B001+SI-B003± Chemotherapy) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase 2, Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Status: Terminated, Estimated PCD: 2010-05-01
Product
HBI-2376
Clinical trial
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
MRTX1133
Product
Aglatimagene besadenovec
Product
ARAG PET
Product
CX-2009
Product
MRTX1719
Product
GEM3PSCA
Clinical trial
A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥50%
Status: Terminated, Estimated PCD: 2021-07-29
Product
REGN2810/chemo/ipi
Clinical trial
A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-08-11
Clinical trial
A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSCA Marker
Status: Terminated, Estimated PCD: 2023-06-28
Product
Cetuximab
Product
Amivantamab
Product
Viagenpumatucel-L
Clinical trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
Status: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M02D1 for Injection in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase I, Open-label, Multicenter, Dose Escalation and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2023-04-04
Product
BL-M02D1
Product
Entinostat
Clinical trial
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)
Status: Terminated, Estimated PCD: 2020-09-10
Clinical trial
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
Panitumumab
Clinical trial
FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma
Status: Recruiting, Estimated PCD: 2026-06-01
Product
SM08502
Product
FOLFIRI
Product
REGN2810/ipi
Clinical trial
A Phase II, Open-label, Multicenter and Multi-cohorts Study to Evaluate the Efficacy and Safety of PLB1001 in Advanced Non-small Cell Lung Cancer With c-Met Dysregulation
Status: Recruiting, Estimated PCD: 2024-12-31
Product
OR2805
Clinical trial
A Phase 1-2 Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents in Subjects With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2024-04-15
Product
Nazartinib
Clinical trial
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Status: Active (not recruiting), Estimated PCD: 2023-05-11
Clinical trial
A Phase Ib/II, Multicenter, Open-label Study of EGF816 in Combination With INC280 in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer.
Status: Terminated, Estimated PCD: 2020-11-10
Product
TPST-1120
Clinical trial
A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjects With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2022-09-07
Product
TPST-1120 + Nivolumab
Product
Part 2 TPST-1120 + Nivolumab
Clinical trial
An Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
Status: Completed, Estimated PCD: 2023-01-01
Product
Vizimpro
Clinical trial
A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Vizimpro®
Status: , Estimated PCD: 2026-03-01
Product
Vandetanib
Clinical trial
A Phase Ι & IIa, Open-label Study to Evaluate Safety and Efficacy of the Combination Therapy of Allogeneic PB103 and Standard Cancer Treatment in the IIIB/IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Patients
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC
Status: Completed, Estimated PCD: 2008-09-01
Clinical trial
Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Phase III, Double-blind, Randomised Study of SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations
Status: Recruiting, Estimated PCD: 2028-02-01
Product
SH-1028
Product
Personalized mRNA Tumor Vaccine
Clinical trial
A Multicenter, Open Label, Single Arm Phase 2 Study of AB-106 in the Treatment of Locally Advanced and Metastatic NSCLC
Status: Active (not recruiting), Estimated PCD: 2023-12-30
Product
SL-279252
Product
CK-301
Clinical trial
A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
Status: Recruiting, Estimated PCD: 2021-11-18
Clinical trial
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2012-12-31
Product
Eribulin
Product
Donor-Derived NK Cell Infusion
Product
Placebo SH-1028
Clinical trial
Clinical Trial on the Safety and Efficacy of Neoantigen Antigen mRNA Tumor Vaccine in the Treatment of Advanced Esophageal Cancer and Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Status:
Product
Ulixertinib
Product
Zirabev
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of AL2846 Capsules Combined With TQB2450 Injection Compared With Docetaxel Injection in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed With Immunotherapy.
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Prospective, Single-arm, Open-label, Non-interventional, Multicenter, Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Advanced or Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer or Glioblastoma Multiforme.
Status: Not yet recruiting, Estimated PCD: 2025-05-16
Clinical trial
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The "DURGA" Trial)
Status: Completed, Estimated PCD: 2021-05-03
Product
Steroid Containing Mouthwash
Clinical trial
A Multi-Center, Randomized, Double-Blind, Phase III Study of Platinum-Containing Chemotherapy With or Without CS1001 in Stage IV Non-Small Cell Lung Cancer Subjects
Status: Active (not recruiting), Estimated PCD: 2023-05-15
Product
CS1001
Product
HH2710
Clinical trial
Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients With Advanced Tumors
Status: Terminated, Estimated PCD: 2023-03-31
Product
AB-106
Clinical trial
A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Status: Completed, Estimated PCD: 2021-08-18
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-02-08
Product
BCD-201
Clinical trial
A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 With or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Multicenter, Double-Blind, Randomized Clinical Study to Evaluate the Pharmacokinetics and Safety of BCD-201 (JSC BIOCAD, Russia) and Keytruda® in Patients With Different Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2022-06-21
Product
ST-067
Product
TJ004309
Product
VIC-1911
Product
Rhenium
Product
MT-6402
Product
Systemic Treatment
Clinical trial
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Phase II Clinical Trial of SHR-1701 With or Without Famitinib in the Treatment of Advanced or Metastatic NSCLC
Status: Withdrawn, Estimated PCD: 2021-11-15
Product
APG-2449
Product
SHR-1701，Famitinib
Clinical trial
A Phase 1a/1b Study of Aurora Kinase A Inhibitor VIC-1911 Monotherapy and in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2023-08-26
Clinical trial
Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
Status: Recruiting, Estimated PCD: 2009-06-20
Product
Donor-derived NK cell infusion
Clinical trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Status: Recruiting, Estimated PCD: 2026-08-30
Clinical trial
A Biomarker Study of Low-Dose IL-2 Plus Pembrolizumab in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2025-01-07
Clinical trial
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers
Status: Recruiting, Estimated PCD: 2026-03-31
Product
OC-001
Clinical trial
A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (Anti-BTLA Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-01
Product
HFB200603
Clinical trial
An Open-label, Single-center, Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of RC48-ADC Combined With Pyrotinib in Local Advanced or Metastasis NSCLC With HER2 Mutation
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
Pyrotinib
Product
RC48-ADC
Product
Saline Solution
Clinical trial
: Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma
Status: Completed, Estimated PCD: 2023-01-27
Product
Meta-genomic signature of intestinal flora
Clinical trial
A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-04-01
Product
P-MUC1C-ALLO1 CAR-T cells
Clinical trial
A Single-center, Prospective Study of the Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant Non-small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Product
Furmonertinib
Clinical trial
Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study
Status: Completed, Estimated PCD: 2023-09-15
Product
Rimiducid
Clinical trial
Phase I Study of MIDRIXNEO-LUNG, an Autologous Neoantigen-targeted Dendritic Cell Immunotherapy in Patients With Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Product
Dendritic cell immunotherapy
Product
Antigen-specific DTH
Product
Control DTH
Clinical trial
Boosting Immune Response With Copanlisib in Locally Advanced Unresectable Non-Small Cell Lung Cancer Receiving Durvalumab, A Phase Ib Study
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Drug
AN0025
Product
Copanlisib
Clinical trial
Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
Status: Recruiting, Estimated PCD: 2025-03-31
Drug
Monalizumab
Clinical trial
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-08-26
Product
LY4101174
Clinical trial
A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ALK Rearranged Advanced Non Squamous Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-01-01
Product
Immunity Therapy
Clinical trial
A Prospective Study of Adebrelimab Combined With Bevacizumab and Docetaxel in the Treatment of Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy
Status: Not yet recruiting, Estimated PCD: 2025-06-30
Product
Adebrelimab
Clinical trial
Synergistic Real-World Study and Evidence-based Medicine Evaluation of Elemene Combined With Tyrosine Kinase Inhibitors（TKIs）in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): Prospective Study
Status: Recruiting, Estimated PCD: 2025-09-30
Product
Elemene
Product
EGFR-TKIs
Clinical trial
IFN-y PET Imaging: Bench to Bedside
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Product
[89Zr]Zr-DFO-emapalumab
Clinical trial
A Phase I/Phase II Study of Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Status: Not yet recruiting, Estimated PCD: 2026-08-27
Product
Nintedanib
Clinical trial
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer (NeoLazer): a Phase II, Randomized, Multi-center Study
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Product
Lazertinib+Pemetrexed+Carboplatin
Drug
Lazertinib
Clinical trial
Biological Characterization of Advanced ALK-rearranged Non-small Cell Lung (NSCLC) Cancer Included in EXPLOREALK Study
Status: Recruiting, Estimated PCD: 2027-06-30
Product
RNAseq
Clinical trial
A Phase 2 Study of MLN4924 (Pevonedistat) in Combination With Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated With Immunotherapy
Status: Active (not recruiting), Estimated PCD: 2022-09-07
Drug
Tiragolumab
Product
Pevonedistat
Clinical trial
Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2022-12-15
Clinical trial
BRIGHTSTAR: A Pilot Trial of Local Consolidative Therapy (LCT) With Brigatinib in Tyrosine Kinase Inhibitor-Naive ALK-Rearranged Advanced NSCLC
Status: Active (not recruiting), Estimated PCD: 2026-01-28
Drug
Brigatinib
Clinical trial
A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.
Status: Active (not recruiting), Estimated PCD: 2024-11-30
Product
Atezolizumab-Bevacizumab
Clinical trial
Phase Ib/II Study of Safety and Efficacy of EZH2 Inhibitor, Tazemetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Product
Tazemetostat
Clinical trial
Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing: a Non-randomized, Open-label, Single-arm Phase II Study
Status: Recruiting, Estimated PCD: 2029-11-01
Clinical trial
The Efficacy and Safety of Stereotactic Radiotherapy Combined With Puterizumab in Non Small Cell Lung Cancer With Intrapulmonary Metastasis：A Phase II Prospective Single Arm Clinical Study
Status: Not yet recruiting, Estimated PCD: 2026-12-30
Product
Puterizumab
Clinical trial
A Single-Center, Prospective, Single-Arm, Observational Study Evaluating the Efficacy and Safety of Osimertinib Combined With Etoposide as First-Line Treatment in Patients With Osimertinib-Resistant or -Insensitive, Advanced EGFR-Mutant Non-Small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2029-06-01
Drug
Osimertinib
Clinical trial
A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-03-30
Product
Tobemstomig
Clinical trial
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2025-02-28
Drug
Cisplatin
Clinical trial
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-08-01
Product
DNA Extraction
Clinical trial
An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations
Status: Terminated, Estimated PCD: 2022-10-30
Product
Tipifarnib
Clinical trial
A Phase 1b Study of Ensartinib in Combination With Platinum-Based Chemotherapy and Bevacizumab in ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2027-09-23
Clinical trial
A Single-arm Pilot Study of Patients With Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) With KEAP1 Mutation Treated With Carbonizumab Combined With Chemotherapy as the First-line Treatment
Status: Recruiting, Estimated PCD: 2025-06-01
Product
cadonilimab
Clinical trial
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2033-12-30
Product
Montanide ISA-51 VG
Clinical trial
A Phase I/II Study of Pembrolizumab and Vorinostat in Patients With Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC
Status: Active (not recruiting), Estimated PCD: 2024-01-21
Product
Vorinostat
Clinical trial
Phase 1 Trial of MK-2870 as Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Subjects With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-06
Product
Sacituzumab tirumotecan
Clinical trial
Prediction of Immunotherapy Efficacy Based on Transcriptome of CX3CR1+T Cell in Peripheral Blood
Status: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) as First-Line Therapy in Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
Tegavivint
Clinical trial
Intensified Chemo-immuno-radiotherapy With Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II Study (PACIFIC BRAZIL)
Status: Active (not recruiting), Estimated PCD: 2024-09-02
Product
H1299 Cell Lysates
Drug
N-803
Clinical trial
Combining an Immune Checkpoint Inhibitor With SBRT or Hypo-fractionated RT in the Treatment of Stage I-III NSCLC: an Exploratory Study on Radiation Dose and Treatment Efficacy.
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Targeted Agent
Clinical trial
Phase II Feasibility Study of Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC
Status: Not yet recruiting, Estimated PCD: 2029-07-31
Product
Fecal Microbiota Transplant
Clinical trial
A Multi-center, Prospective, Exploratory Study Evaluating the Efficacy and Safety of a Modified Si Jun Zi Tang Formula in the Perioperative Treatment of Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Modified Si Jun Zi Tang
Clinical trial
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Status: Active (not recruiting), Estimated PCD: 2028-12-31
Clinical trial
A Phase 2 Study of Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic Non-Small Cell Lung Carcinoma
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Single-arm, Phase II Clinical Study of Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
Status: Not yet recruiting, Estimated PCD: 2025-11-20
Drug
PD-1 antibody
Clinical trial
Phase I Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Administered Concurrently With Pembrolizumab
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Product
PANDA-VAC
Clinical trial
Immune-modulatory Radiotherapy to Enhance the Effects of Neoadjuvant PD-L1 Blockade After Neoadjuvant Chemotherapy in Patients With Resectable Stage III(N2) Non-small Cell Lung Cancer (NSCLC): A Multicenter Phase II Trial
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase II Clinical Trial Evaluating the Efficacy of Cadonilimab in Combination With Pemetrexed and Anlotinib for Treatment of Elderly Patients With T790M-negative Advanced Non-squamous Non-small Cell Lung Cancer Following Resistance to EGFR-TKI.
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Cadonilimab plus Pemetrexed and Anlotinib
Clinical trial
A Single-Arm, Phase II Study of AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
AK104
Product
Albumin-Bound Paclitaxel
Clinical trial
Randomized Phase II Study of Standard Chemotherapy With Docetaxel With or Without Bintrafusp Alfa in Patients With Advanced NSCLC After Progressing on a Combination of Anti-PD-1/PD-L1 Agents and Chemotherapy
Status: Terminated, Estimated PCD: 2023-12-31
Product
Bintrafusp Alfa
Drug
Docetaxel
Clinical trial
A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-12-27
Product
Flt3/MerTK Inhibitor MRX-2843
Clinical trial
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers: Phase 2 Randomized Trial (VALUE-CHECK)
Status: Not yet recruiting, Estimated PCD: 2029-03-30
Product
Extended Dosing Interval
Product
Standard of Care
Clinical trial
A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid Tumors
Status: Recruiting, Estimated PCD: 2027-12-01
Product
KK2269
Clinical trial
A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Pembrolizumab + Bevacizumab
Clinical trial
A Phase 2 Open-label Study to Determine the Central Nervous System Efficacy of Capmatinib in NSCLC Patients With Brain Metastases With cfDNA Positive MET Alterations
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Pilot Study of Perfusion CT for Lung Tumors Treated With Stereotactic Ablative Radiation Therapy (SABR)
Status: Completed, Estimated PCD: 2020-04-29
Product
Isovue-200
Clinical trial
A Phase 2 Trial of SX-682 and Pembrolizumab in Patients With Treatment Naive Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2027-07-01
Product
SX-682
Clinical trial
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2021-09-23
Product
MUC1 Peptide-Poly-ICLC Vaccine
Clinical trial
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Drug
Erlotinib
Drug
Trastuzumab
Clinical trial
Integrative Analysis of the Tumor Microenvironment and Optimization of the Immunotherapy Duration in Non-small Cell Lung Cancer Patients (OPTIMUNE-LUNG Study)
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Product
ICI treatment
Product
ICI
Clinical trial
Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2023-06-22
Drug
Sitravatinib
Clinical trial
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Status: Recruiting, Estimated PCD: 2028-05-01
Clinical trial
A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Papaverine
Clinical trial
Combined MEK Inhibitor Trametinib and RTK Inhibitor Anlotinib Therapy in Non-G12C KRAS-Mutant Non-Small Cell Lung Cancer Patients
Status: Completed, Estimated PCD: 2023-07-01
Product
Trametinib
Clinical trial
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
Status: Completed, Estimated PCD: 2012-04-01
Product
F18-FPPRGD2
Clinical trial
Phase II Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2023-09-12
Clinical trial
Qualitative Study on Experiences Related to Anorexia and the Effects of Anamorelin and Placebo in Advanced Non-Small-Cell Lung Cancer Patients With Anorexia-Cachexia: A Preliminary Study
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Prospective Clinical Study of Anlotinib Hydrochloride Capsule Combined With Penpulimab Injection in the Front-line Treatment of Advanced Non-small Cell Lung Cancer Patients
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Anlotinib + Penpulimab
Clinical trial
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Prospective Study of Savolitinib Plus Docetaxel in Pretreated EGFR/ALK/ROS1/MET ex14m-wildtype Advanced NSCLC Patients With MET Overexpression (FirstMET)
Status: Recruiting, Estimated PCD: 2027-08-31
Clinical trial
Adjuvant Therapy of Ensatinib in Patients With Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer: a Prospective, Multi-center, Single-arm Exploratory Study
Status: Recruiting, Estimated PCD: 2027-02-01
Product
Trastuzumab emtansine
Product
Pertuzumab
Product
Lapatinib
Product
Everolimus
Drug
Anlotinib
Product
Palbociclib
Product
Ponatinib
Product
Vismogedib
Product
Itacitinib
Product
Ipatasertib
Drug
Entrectinib
Clinical trial
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-11-28
Clinical trial
A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2026-09-01
Product
HTL0039732
Clinical trial
Multicenter Phase III, Randomized Study to Evaluate Treatment Customized According to RAP80 and BRCA1 Assessment in Patients With Advanced Non-small-cell Lung Cancer
Status: Terminated, Estimated PCD: 2015-04-01
Product
Gemcitabine, Cisplatin
Clinical trial
A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Status: Completed, Estimated PCD: 2023-11-30
Drug
Abexinostat
Product
Pemigatinib
Product
Oncology Drugs
Drug
Pralsetinib
Product
Talazoparib
Drug
Alpelisib
Clinical trial
Phase II Clinical Trial Evaluating Intravenous AZD9150 (Antisense STAT3) With MEDI4736 (Anti-PD-L1) in Patients With Advanced Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2025-04-30
Drug
Danvatirsen
Clinical trial
A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818 (Catequentinib) to Nivolumab in Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Assessing the Immunomodulatory Effects of Pharmacologic Ascorbate With Durvalumab (MEDI 4736) in Non-Small Cell Lung Cancer: A Window of Opportunity Trial
Status: Recruiting, Estimated PCD: 2027-10-01
Product
Pharmacological Ascorbate
Clinical trial
A Phase 2, Open-label, Single Arm Study to Investigate the Safety and Efficiency of Golidocitinib in Combination With Sintilimab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With PD-L1TPS ≥ 1%)
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Drug
Golidocitinib
Clinical trial
A Pilot Study of Neoadjuvant High Dose Vitamin A for Resectable Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2022-12-09
Product
Vitamin A
Clinical trial
Phase I/II Trial Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Product
Selumetinib
Clinical trial
An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)
Status: Recruiting, Estimated PCD: 2025-02-24
Drug
cyclophosphamide
Clinical trial
An Open-Label Phase 1b Dose-Finding Trial Evaluating the Safety of Niraparib and Temozolomide and Atezolizumab in Participants With Advanced Solid Tumors and Expansion to a Phase 2 Trial Comparing the Effects of Niraparib and Temozolomide Plus Atezolizumab vs. Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (TRIO-US L-06)
Status: Recruiting, Estimated PCD: 2025-01-03
Product
TMZ
Clinical trial
An Observational Clinical Study of Increasing Stereotactic Radiotherapy in Patients With Advanced Non-small Cell Lung Cancer After Treatment With PD-1 Inhibitors And Evaluation of Stable Disease
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat (OSIBOOST-2)
Status: Recruiting, Estimated PCD: 2026-06-01
Product
Cobicistat
Clinical trial
MITRIC: Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clincal Responders
Status: Recruiting, Estimated PCD: 2034-03-31
Clinical trial
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR Clinical Study)
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
Ceralasertib
Product
DOCETAXEL
Clinical trial
Priming Immunotherapy in Advanced Disease With Radiation
Status: Active (not recruiting), Estimated PCD: 2024-02-16
Product
Immune checkpoint inhibitor
Clinical trial
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance on Third-generation EGFR TKI： a Single-arm Phase II Trial
Status: Recruiting, Estimated PCD: 2025-12-15
Product
Osimertinib + Dalpiciclib
Clinical trial
A Phase II Study of Poziotinib and Ramucirumab in EGFR Exon 20 Mutant Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Withdrawn, Estimated PCD: 2023-02-02
Product
Poziotinib
Clinical trial
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Atezolizumab in Advanced NSCLC and Mesothelioma Progressing Under Immune-checkpoint Inhibitors or Gemcitabine. A Multicenter, Single-arm, Open Label Phase II Trial With Two Cohorts
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Drug
Gemcitabine
Clinical trial
Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pimasertib for Treatment of Intracranial Metastases
Status: Completed, Estimated PCD: 2023-12-08
Clinical trial
A Phase Ib/II Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab in Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2027-11-21
Product
Phase Ib ARRY-614 + nivolumab
Product
ARRY-614 + Nivolumab + Ipilimumab
Product
Phase II ARRY-614 + Nivolumab
Product
Phase II ARRY-614 + Nivolumab + Ipilimumab
Product
Phase II ARRY-614 + Nivolumab + Ipilimumab (RCC)
Clinical trial
An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC
Status: Not yet recruiting, Estimated PCD: 2029-10-01
Product
Tremelimumab
Clinical trial
A Platform Study of DNA Damage Response Inhibitors in Combination With Conventional Radiotherapy in Non Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-04-01
Drug
AZD1390
Drug
Ceralasertib
Drug
AZD5305
Clinical trial
Phase I Study of High Efficient Killing Cell Therapy for Advanced Non Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-05-01
Product
HEKT
Clinical trial
Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Image-Guided Hypofractionated Radiotherapy With Stereotactic Boost and Chemotherapy for Inoperable Stage II-III Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Drug
carboplatin
Drug
paclitaxel
Clinical trial
A Phase Ib Dose De-Escalation Study of All-Trans Retinoic Acid (ATRA) and Atezolizumab in Patients With Advanced Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Tretinoin
Clinical trial
A Phase 1/2 Study of Combination Osimertinib and Bevacizumab as Treatment for Patients With EGFR-mutant Lung Cancers
Status: Completed, Estimated PCD: 2022-03-01
Clinical trial
A Pilot Study of Biomarker Evaluation and Safety of Pre-Incisional Ketorolac for Patients Undergoing Surgical Resection for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Ketorolac
Clinical trial
(TESSERACT): Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TBI)
Status: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
A Phase II Multi-Centre Study Evaluating the Efficacy of Dacomitinib for Patients With Epidermal Growth Factor Receptor (EGFR)-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expression or Other Novel Emerging Biomarkers
Status: Recruiting, Estimated PCD: 2025-07-01
Product
Dacomitinib
Clinical trial
A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second or Third Line Treatment for Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
Cisplatin or Carboplatin
Clinical trial
A Phase I/Ib Trial of Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Status: Active (not recruiting), Estimated PCD: 2021-05-09
Drug
Pirfenidone
Clinical trial
An Open-label, Single-Center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted Antibodies
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Novel Dynamic PET Kinetics and MRI Radiomics Analyses in Brain Tumors
Status: Completed, Estimated PCD: 2023-09-18
Product
18F-FMAU
Clinical trial
Sunvozertinib Combined With Chemotherapy for EGFRm + Locally Advanced or Metastasis NSCLC Patients After EGFR-TKI Treatment Failure：Phase I/II (WU-KONG36)
Status: Recruiting, Estimated PCD: 2025-12-01
Drug
Sunvozertinib
Clinical trial
A Phase Ⅱ Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-06-30
Drug
Adebrelimab
Clinical trial
Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors
Status: Active (not recruiting), Estimated PCD: 2024-02-21
Product
Vorolanib
Clinical trial
A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former Smokers
Status: Completed, Estimated PCD: 2020-03-05
Product
Iloprost
Product
Plinabulin
Clinical trial
Exploratory Study of Adibelimab Combined With Famitinib and Chemotherapy for the Treatment of Patients With Driver Gene-Negative Locally Advanced or Metastatic NSCLC Progressing After PD-1 Monoclonal Antibody Combined With Chemotherapy
Status: Not yet recruiting, Estimated PCD: 2024-07-31
Product
Adibelimab
Clinical trial
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Product
89Zr-Patritumab deruxtecan
Clinical trial
Efficacy and Biomarker Explanation of IBI-323 Combined With Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged Non-Small Cell Lung Cancer Who Failed From First Line Alectinib
Status: Recruiting, Estimated PCD: 2025-12-10
Product
IBI-323 + Bevacizumab + Platinum
Clinical trial
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Status: Active (not recruiting), Estimated PCD: 2024-02-06
Clinical trial
A Randomized, Multicenter, Exploratory Clinical Study for The Primary And Secondary Prevention of Febrile Neutropenia (FN) With Efbemalenograstim Alfa in Patients With Non-small Cell Lung Cancer (NSCLC) at Moderate Risk Undergoing Chemotherapy Regimens With Associated Risk Factors
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Product
Efgbemalenograstim
Product
Neoantigen Peptide Vaccine
Clinical trial
Observational Retro-prospective Study on Programmed Cell Death 1/ Programmed Cell Death Ligand1 (PD1/PDL1) Inhibitors Treatment Duration in Patients With Non Small Cell Lung Carcinoma
Status: Recruiting, Estimated PCD: 2024-11-30
Product
Carboplatin/Cisplatin
Clinical trial
A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer - (IM-BATTLE-2 Program)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-09-30
Product
VET3-TGI
Clinical trial
A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Encorafenib
Product
Binimetinib
Clinical trial
A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLC
Status: Recruiting, Estimated PCD: 2025-12-09
Product
Anti-PD-(L)1
Clinical trial
A Proof-of-concept Trial With Safety Run of Tepotinib and Pembrolizumab in NSCLC Patients With and Without MET Exon 14 Mutations (POTENT)
Status: Recruiting, Estimated PCD: 2028-02-01
Clinical trial
Mass Balance Study of [14C]TGRX-326 in Healthy Adult Chinese Male Participants
Status: Not yet recruiting, Estimated PCD: 2024-08-15
Product
[14C]TGRX-326
Clinical trial
A Pilot Study of FDG-PET Variability to Establish Biology-Guided Treatment Planning Feasibility for Stereotactic Body Radiation Therapy
Status: Completed, Estimated PCD: 2019-03-19
Product
Fludeoxyglucose F-18
Clinical trial
Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive Non-small Cell Lung Cancer Patients With Asymptomatic Brain Metastases
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Endobronchial Ultrasound Transbronchial Needle Guided Interstitial Photodynamic Therapy for Palliation of Locally Advanced Lung Cancer and Advanced Cancers Obstructing the Airway -Phase I/II
Status: Recruiting, Estimated PCD: 2030-02-12
Product
Porfimer
Clinical trial
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Status: Recruiting, Estimated PCD: 2025-07-01
Product
EP0057
Clinical trial
A Randomized, Controlled, Double-blind, Double-simulated, Multicenter Phase III Clinical Study Evaluating D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure.
Status: Recruiting, Estimated PCD: 2026-10-01
Product
D-1553
Clinical trial
Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Phase 1 Trial of Osimertinib With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From EGFR Positive Non-Small-Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2022-04-01
Clinical trial
A Phase II Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Status: , Estimated PCD: 2029-01-01
Drug
GT103
Clinical trial
FLT3 Ligand (CDX-301), CD40 Agonist Antibody (CDX-1140), and Stereotactic Radiotherapy Versus Standard Therapy for Advanced Non-small Cell Lung Cancer: A Phase I/II Randomized Trial
Status: Terminated, Estimated PCD: 2022-08-18
Product
FLT3 Ligand
Clinical trial
Phase II Concurrent Durvalumab (MEDI4736) and Radiotherapy Followed by Consolidative Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
A Prospective, Phase II Study of Bevacizumab Combined With Fractionated Stereotactic Radiotherapy in Patients With 1 to 10 Brain Metastases From Non-small Cell Lung Cancer
Status: Completed, Estimated PCD: 2023-03-31
Product
FSRT + Bevacizumab
Clinical trial
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Status: Recruiting, Estimated PCD: 2025-01-31
Product
Memantine
Clinical trial
Transcutaneous Electrical Acupoint Stimulation (TEAS) for the Treatment of Pain in Bone Metastases of Lung Cancer: A Multicenter Prospective RCT Study
Status: Not yet recruiting, Estimated PCD: 2025-04-30
Product
Routine palliative treatment
Clinical trial
HyPeR: A Phase 1, Dose Escalation Study of Guadecitabine /ASTX727 in Combination With Pembrolizumab (MK3475) in Patients With Refractory Solid Tumours
Status: Recruiting, Estimated PCD: 2026-09-01
Product
Guadecitabine
Clinical trial
Phase 2 Trial of ZEN003694 in Squamous Cell Lung Cancer Patients Harboring NSD3 Amplification
Status: Recruiting, Estimated PCD: 2025-11-01
Drug
ZEN003694
Clinical trial
Real World Study to Evaluate the Efficacy and Resistant Mechanism of Erlotinib/Gefitinib Combined With Bevacizumab in First Line EGFR Mutation Positive Advanced Non-aquamous Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-08-31
Product
Erlotinib + Gefitinib + Bevacizumab
Clinical trial
A Multicentre Single-arm Phase II Trial of Amivantamab, Lazertinib Plus Bevacizumab in Patients With EGFR-mutant Advanced NSCLC With Progression on Previous Third-generation EGFR-TKI
Status: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
A Phase II Study of Fingolimod in Patients With Non-Small Cell and Small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2026-05-31
Product
Fingolimod
Clinical trial
IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Carotuximab
Clinical trial
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Product
Ezabenlimab
Clinical trial
A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination With Anti-PD1 Therapy in Patients With Advanced NSCLC or Squamous Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2027-12-09
Clinical trial
Resection of Pulmonary Lesions Aided by Robotic Bronchoscopy With Cone CT and INdocyanin Green (REPLACING) Study
Status: Withdrawn, Estimated PCD: 2023-12-27
Product
Indocyanine Green
Clinical trial
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Status: Recruiting, Estimated PCD: 2027-08-01
Product
Data and Specimen Collection
Product
Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Clinical trial
Phase 1 Trial of Umbilical Cord Blood Natural Killer Cells (CB-NK) Expressing Soluble IL-15 (sIL-15) and PD-L1 +/- Atezolizumab in Non-Small Cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Product
Antineoplastic Immune Cell
Clinical trial
The BE WELL Study: Black Raspberry Beverage Working to Prevent Lung Cancer
Status: Completed, Estimated PCD: 2021-05-13
Clinical trial
The Impact of Intravenous Administration of Perioperative Acetaminophen and Ibuprofen Combination (Maxigesic®) on Postoperative Delirium in Elderly Patients Undergoing Minimally Invasive Lung Segmentectomy or Lobectomy
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Acetaminophen + Ibuprofen
Product
Normal saline
Clinical trial
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity - DARWINII
Status: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
the Association of Psychological Distress in Patients With Advanced Lung Cancer Treated With Immunotherapy or Targeted Therapy
Status: Recruiting, Estimated PCD: 2027-12-31
Drug
immunotherapy
Product
Targeted Therapy Agent
Drug
ASTX727
Clinical trial
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-07
Product
XB002
Clinical trial
Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy (LCT) for Patients With EGFR-Mutant Metastatic NSCLC (NORTHSTAR)
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-02-03
Product
Avapritinib
Clinical trial
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Molecular Characterization and Clinical Outcomes of ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Single Arm Phase 2 Trial of Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib (TOP 1901)
Status: Terminated, Estimated PCD: 2022-11-13
Clinical trial
Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Randomized Trial Comparing Two Radiotherapy Schedules
Status: Completed, Estimated PCD: 2023-07-05
Product
PET-based, dose-painted, accelerated chemoradiotherapy
Clinical trial
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab for Patients With Resectable Stage IB - III Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-04-15
Product
Chemoradiotherapy
Clinical trial
A Phase II Study of Circulating Tumor DNA Directed Consolidation Durvalumab (MEDI4736) Following Induction and Concurrent Durvalumab With SABR for Stage I NSCLC. SCION: SABR and Checkpoint Inhibition Of NSCLC
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Quantification of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Metastasis of Breast Carcinoma Patients and Assessment of Repeatability (VUBAR) - Pilot Study
Status: Recruiting, Estimated PCD: 2024-11-01
Product
68GaNOTA-Anti-HER2
Clinical trial
Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
Standard of care
Clinical trial
An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2017-11-10
Product
Veliparib
Clinical trial
Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2019-07-02
Product
Decitabine
Product
Tetrahydrouridine
Clinical trial
Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2029-01-12
Product
sac-TMT
Clinical trial
A Phase II, Open-Label, Single-Arm, Prospective Clinical Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Consolidation Treatment in Patients With Locally Advanced, Unresectable NSCLC Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy
Status: Terminated, Estimated PCD: 2022-06-27
Clinical trial
Phase II Study of Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
Status: Withdrawn, Estimated PCD: 2025-03-01
Clinical trial
Durvalumab With Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART)
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970, Berzosertib) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2021-08-23
Product
Berzosertib
Clinical trial
Pilot Study of the Safety and Feasibility of Administering Concurrent Chemotherapy and Accelerated Hypofractionated Radiation Therapy in the Treatment of Medically Inoperable T2A-T4 N0 Non-small Cell Lung Cancer.
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Disitamab Vedotin（RC48）Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Product
Disitamab Vedotin
Product
third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
Drug
pyrotinib
Clinical trial
Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
GSTP1 A313G
Clinical trial
Randomized Phase II Study of Durvalumab (MEDI 4736) and Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Status: Recruiting, Estimated PCD: 2026-06-01
Drug
Abraxane
Clinical trial
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Status: Active (not recruiting), Estimated PCD: 2022-04-14
Drug
T-VEC
Clinical trial
Recurrence Free Survival After Curative Resection of Non-small Cell Lung Cancer Between Inhalational Gas Anesthesia and Propofol-based Total IntraVenous Anesthesia: a Multicenter, Randomized, Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2028-12-31
Product
Propofol
Product
Inhaled anesthetics
Clinical trial
Light Dosimetry for Intraoperative Photodynamic Therapy (IO-PDT) With Porfimer Sodium (Photofrin) in Patients With Malignant Mesothelioma or Non-Small Cell Lung Cancer (NSCLC), or Other Malignancies With Pleural Disease - Phase I Study
Status: Active (not recruiting), Estimated PCD: 2023-11-13
Product
Porfimer Sodium
Clinical trial
Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)
Status: Recruiting, Estimated PCD: 2030-04-01
Product
Botensilimab + Balstilimab
Clinical trial
Tisch Cancer Institute - BMS Study # CA027-005: Neoadjuvant Nivolumab + BMS-813160 (CCR2/5-inhibitor) or BMS-986253 (Anti-IL-8) for NSCLC or HCC
Status: Completed, Estimated PCD: 2023-11-16
Product
BMS-813160
Product
BMS-986253
Clinical trial
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Phase 1 Trial of Dose Escalated BGB324 in Combination With Docetaxel for Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2023-02-06
Product
BGB324
Clinical trial
Nano-SMART: An Adaptive Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Centrally Located Lung Tumors and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma
Status: Recruiting, Estimated PCD: 2026-04-10
Product
AGuIX
Drug
olaparib
Clinical trial
89Zr-pembrolizumab-PET Imaging in Patients With Locally Advanced or Metastatic Melanoma or Non-small Cell Lung Cancer
Status: Completed, Estimated PCD: 2019-03-01
Product
89Zr-Pembrolizumab
Clinical trial
Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-01
Product
PRO1184
Clinical trial
Metformin for Chemoprevention of Lung Cancer in High-Risk Overweight or Obese Individuals
Status: Recruiting, Estimated PCD: 2026-04-01
Product
Metformin
Clinical trial
A Phase I/Ib Study of APX005M in Combination With Nivolumab and Cabiralizumab in Patients With Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD- 1/PD-L1 Therapy
Status: Active (not recruiting), Estimated PCD: 2022-01-05
Product
APX005M
Product
Cabiralizumab
Clinical trial
Phase II Trial of Pevonedistat (TAK-924) Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2021-11-04
Clinical trial
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
18F-αvβ6-BP
Clinical trial
Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Lung Cancer During Surgical Procedures
Status: Recruiting, Estimated PCD: 2027-02-01
Product
Panitumumab-IRDye800
Clinical trial
A Phase 2 Trial to Assess Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases.
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Product
Trastuzumab deruxtecan
Clinical trial
A Phase1/2a Study of Rigosertib Plus Nivolumab in Stage IV Lung Adenocarcinoma Patients With KRAS Mutation Who Progressed on First-Line Treatment
Status: Completed, Estimated PCD: 2023-12-20
Product
Rigosertib
Clinical trial
Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial
Status: Recruiting, Estimated PCD: 2024-12-02
Clinical trial
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Neoadjuvant Camrelizumab Plus Apatinib or Platinum-based Chemotherapy for Potentially Resectable (Resectable and Initially Unresectable) II-III Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2022-06-29
Product
Camrelizumab
Clinical trial
Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Adjuvant Treatment in Cancer Patients With Neoantigen-primed DC Vaccine : a Single-arm, Open-label, Prospective Clinical Trial
Status: Recruiting, Estimated PCD: 2025-12-31
Product
DC vaccine
Clinical trial
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Status: Completed, Estimated PCD: 2023-12-01
Clinical trial
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase III Study to Evaluate and Compare the Efficacy and Safety of SY-3505 Versus Crizotinib in Treatment-Naive Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Product
SY-3505
Clinical trial
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Serplulimab
Product
Liposomal paclitaxel
Clinical trial
Heterogeneity of Dendritic Cells and Other Cells of Myeloid and Lymphoid Origin in Colon and Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-02-09
Product
Single cell transcriptomics
Clinical trial
Erector Spinae Blocks for Thoracic Surgery
Status: Recruiting, Estimated PCD: 2024-07-21
Product
ESB Thoracic
Clinical trial
A Prospective, Single-arm PhaseⅡTrial of Neoadjuvant/Adjuvant Pembrolizumab Plus Platinum-doublet Chemotherapy (Chemo) in IIa-IIIb NSCLC
Status: Active (not recruiting), Estimated PCD: 2023-12-08
Clinical trial
A Single Arm Phase II Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
Status: Completed, Estimated PCD: 2022-10-12
Clinical trial
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-09-21
Clinical trial
CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors: CHEERS-trial
Status: Completed, Estimated PCD: 2022-02-01
Clinical trial
A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Status: Recruiting, Estimated PCD: 2027-12-30
Product
HBI 0201-ESO TCRT
Clinical trial
An Investigator-Sponsored Phase 2 Single Arm Trial of Ramucirumab and Pembrolizumab in Patients With EGFR Mutant Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-08-19
Clinical trial
The Efficacy and Safety of Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIB-IIIA Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-05-30
Clinical trial
A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.
Status: Active (not recruiting), Estimated PCD: 2027-11-30
Clinical trial
A Pilot Trial of Electronic Cigarettes in Patients Diagnosed With Cancers of the Head, Neck, and Lung
Status: Withdrawn, Estimated PCD: 2024-01-31
Clinical trial
A Phase II, Prospective, Multi-centre, Study to Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Status: Recruiting, Estimated PCD: 2026-12-01
Drug
pemetrexed
Clinical trial
An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation
Status: Recruiting, Estimated PCD: 2026-08-01
Product
Autologous, engineered T Cells targeting TP53 R175H
Clinical trial
A Randomized, Phase 2 Trial of Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy (CHAMELEON)
Status: Not yet recruiting, Estimated PCD: 2024-09-01
Drug
interleukin-2
Clinical trial
A Phase II Study of Concurrent Chemoradiation Plus Durvalumab (MEDI4736) Followed by Surgery Followed by Adjuvant Durvalumab (MEDI4736) in Medically Operable Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2021-10-30
Clinical trial
Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Product
ZM008
Clinical trial
A Randomized Phase II Study of Carboplatin and Pemetrexed w/ or w/o Selpercatinib in Participants With Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)
Status: Recruiting, Estimated PCD: 2023-06-27
Clinical trial
Gumarontinib Combined With Third-generation EGFR-TKI in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Amplification Following EGFR-TKI Treatment Failure.
Status: Not yet recruiting, Estimated PCD: 2027-12-12
Clinical trial
Adjuvant Chemotherapy Versus Observation in Fully Resected Stage I Lung Adenocarcinoma With High Risk of Post-operative Recurrence
Status: Recruiting, Estimated PCD: 2024-01-01
Product
Cisplatin + Pemetrexed
Product
Nicotine Replacement
Product
gumarontinib
Product
third-generation EGFR-TKI
Clinical trial
Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer: A Randomized Phase II Study
Status: Terminated, Estimated PCD: 2022-09-30
Product
Pemetrexed or Nab-paclitaxel
Clinical trial
A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer
Status: Completed, Estimated PCD: 2020-10-21
Product
NK cell and PD-1 antibody
Clinical trial
DISCERN: Dual Immune Strategy Versus Single Checkpoint Inhibition Efficacy Response in PDL-1 Negative Non-Small Cell Lung Cancer (NSCLC)
Status: Not yet recruiting, Estimated PCD: 2027-01-30
Drug
mFOLFOX6
Clinical trial
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Status: Recruiting, Estimated PCD: 2027-12-31
Drug
ADI-PEG 20
Clinical trial
Analysis of Survival Status of KRAS Mutation Advanced Non-small Cell Lung Cancer Based on NGS Test Results in Hunan Province, China
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Chemotherapy.
Clinical trial
Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)
Status: Not yet recruiting, Estimated PCD: 2027-06-15
Product
Targeted TKI therapy
Clinical trial
A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Product
Poly ICLC
Clinical trial
Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer (PRIMM Study)
Status: Recruiting, Estimated PCD: 2024-12-31
Product
chemotherapy + immune checkpoint inhibitors
Clinical trial
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC
Status: Recruiting, Estimated PCD: 2028-12-01
Product
Difluoromethylornithine
Clinical trial
Cambridge Brain Mets Trial 1: A Proof-of-principle Phase 1b/Randomised Phase 2 Study of Afatinib Penetration Into Cerebral Metastases for Patients Undergoing Neurosurgical Resection, Both With and Without Prior Low-dose, Targeted Radiotherapy
Status: Terminated, Estimated PCD: 2020-08-12
Product
Afatinib
Clinical trial
Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours
Status: Recruiting, Estimated PCD: 2025-06-17
Product
brigimadlin
Clinical trial
An Investigator-sponsored, Phase 1/2 Trial of the Oral XPO1 Inhibitor Selinexor (KPT-330) Monotherapy and in Combination With Docetaxel for Previously Treated, Advanced KRAS Mutant Non-small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2022-11-08
Drug
Selinexor
Clinical trial
A Prospective, Single-arm, Single-center, Exploratory Clinical Study of Tirelizumab Combined With Chemotherapy in First-line Treatment of ECOG PS 2 Points in Relapsed/Metastatic Non-small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2025-04-01
Product
Tirelizumab
Clinical trial
Molecular Studies of Canakinumab in High-Risk Former-Smokers (CANIFS)
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 2 Study of Etirinotecan Pegol (NKTR-102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)
Status: Completed, Estimated PCD: 2018-09-08
Product
Pegylated Irinotecan
Product
Standard of Care PD-1 Therapy
Clinical trial
Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)
Status: Active (not recruiting), Estimated PCD: 2025-05-30
Clinical trial
LCI-LUN-NSC-SBRT-001: Phase II Prospective Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation and Adjuvant Immunotherapy for Locally-Advanced Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-07-12
Clinical trial
A Feasibility Study to Evaluate the Addition of Tumor Treating Fields to Treatment of Locally Advanced Stage III NSCLC
Status: Recruiting, Estimated PCD: 2025-11-15
Clinical trial
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Status: Recruiting, Estimated PCD: 2026-09-15
Clinical trial
A Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Advanced NSCLC Patients
Status: Recruiting, Estimated PCD: 2025-06-30
Product
Sapanisertib
Product
Telaglenastat
Clinical trial
A Pilot Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity
Status: Completed, Estimated PCD: 2023-03-22
Clinical trial
Molecular Analysis for Therapy Choice (MATCH)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
Adavosertib
Clinical trial
A Phase II Study of Efficacy and Safety of Combination of Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2024-07-01
Product
Apatinib + Fluzoparib
Product
Apatinib
Clinical trial
A Phase 1/2 Study of Combination Lorlatinib and Ramucirumab in Patients With Advanced ALK-rearranged Lung Cancers
Status: Recruiting, Estimated PCD: 2028-08-17
Clinical trial
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
Status: Recruiting, Estimated PCD: 2026-11-04
Product
AMG 193
Clinical trial
Fecal Microbiota Transplantation Combined With Immunotherapy and Chemotherapy as First-line Treatment for Driver-gene Negative Advanced Non-small Cell Lung Cancer: a Prospective, Multicenter, Single-arm Exploratory Study (FMT-JSNO-02)
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Product
Fecal Microbiota Transplantation (FMT)
Clinical trial
Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-09-16
Product
BGB-A445
Drug
tislelizumab
Clinical trial
A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2014-07-09
Drug
docetaxel
Product
AZD4547
Clinical trial
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-05-01
Product
BGB-43395
Clinical trial
Phase II Pilot Study of Subsequent Line Gemcitabine and Nivolumab for Advanced SCLC
Status: Terminated, Estimated PCD: 2020-10-07
Drug
Tucidinostat
Clinical trial
Observational Study on the Efficacy and Safety of Huaier Granules Compared With Platinum Containing Dual Drug Combination Chemotherapy in Adjuvant Therapy for Resectable Stage II-IIIA Non-small Cell Lung Cancer After Radical Surgery
Status: Recruiting, Estimated PCD: 2025-09-01
Product
Huaier
Product
Capivasertib
Clinical trial
A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination With Other Anticancer Agents in Participants With Solid Tumors (eVOLVE-01)
Status: Not yet recruiting, Estimated PCD: 2025-08-26
Clinical trial
Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC
Status: Active (not recruiting), Estimated PCD: 2019-04-16
Clinical trial
DZD9008 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With EGFR Mutations: Cohort Study
Status: Recruiting, Estimated PCD: 2025-12-31
Drug
DZD9008
Clinical trial
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Status: Completed, Estimated PCD: 2021-07-16
Clinical trial
Single Arm Phase II Trial Using Canakinumab for the Prevention of Lung Cancer (Can-Prevent-Lung)
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.
Status: Recruiting, Estimated PCD: 2026-12-24
Clinical trial
A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Drug
Etrumadenant
Clinical trial
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-01-01
Product
KSQ-001EX
Clinical trial
IMPORT-201: A Phase 1 First-in-Human Dose Finding/Randomized Phase 2 Study of IMM60 and Pembrolizumab for Advanced Melanoma and Metastatic NSCLC
Status: Terminated, Estimated PCD: 2024-04-22
Product
IMM60
Drug
fludarabine
Clinical trial
Prospective, Single-center, Single-arm Phase 2 Clinical Study on the Efficacy and Safety of Single-agent Neoadjuvant Therapy With Serplulimab in Patients With Non-small Cell Lung Cancer With TPS ≥ 50%.
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Phase 1 Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in the First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-07-26
Product
Histology-Based Chemotherapy Doublet
Clinical trial
Circulating Tumor Cells and Early Diagnosis of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease
Status: Completed, Estimated PCD: 2020-10-13
Product
Isolation of circulating tumor cells (CTC)
Clinical trial
A Phase Ib /II Trial of Pembrolizumab and Idelalisib in Patients With Non-small Cell Lung Cancer (NSCLC) Who Have Failed Immune Checkpoint Inhibitor
Status: Terminated, Estimated PCD: 2020-08-15
Product
Idelalisib
Clinical trial
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
UTD1
Clinical trial
Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase II Study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1
Status: Terminated, Estimated PCD: 2021-06-17
Clinical trial
A Phase II Clinical Trial of Tiragolumab in Combination With Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Phase II Randomized, Open-Labelled, Multicenter Study of Safety & Efficacy of Combination Brigatinib and Carboplatin-Pemetrexed Therapy or Brigatinib Monotherapy as First-Line Treatment in Advanced ALK-Positive Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Brigatinib
Clinical trial
Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting
Status: Active (not recruiting), Estimated PCD: 2023-10-31
Drug
doxorubicin
Clinical trial
A Phase II Study of Subcutaneous Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial Model
Status: Recruiting, Estimated PCD: 2025-12-07
Clinical trial
A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy.
Status: Completed, Estimated PCD: 2016-01-26
Product
Pemetrexed and Reolysin
Product
Docetaxel and Reolysin
Clinical trial
A Single-arm, Multicenter, and Phase II Clinical Study to Evaluate the Efficacy and Safety of Serplulimab Combined With Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable Stage II-IIIA NSCLC
Status: Recruiting, Estimated PCD: 2024-02-28
Clinical trial
A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-08-01
Drug
Metformin
Clinical trial
A Phase II Study to Evaluate the Imaging Potential of 68GaNOTA-Anti-MMR VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Patients With Non-small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2027-04-01
Product
68GaNOTA-Anti-MMR-VHH2
Clinical trial
Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone for Patients With Advanced Non-small Cell Lung Cancer and EGFR Mutations: Phase 3 Randomized Clinical Trial
Status: Recruiting, Estimated PCD: 2024-07-14
Clinical trial
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-03-24
Drug
fluorouracil
Clinical trial
A Phase Ib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Who Are Receiving Standard Chemotherapy Regimens.
Status: Completed, Estimated PCD: 2017-04-18
Clinical trial
Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR
Status: Active (not recruiting), Estimated PCD: 2026-06-30
Clinical trial
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography for Staging, Response Assessment, and Patient Selection in Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-05-31
Product
[18F]-αvβ6-BP
Clinical trial
A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Non Small Cell Lung Carcinoma (NSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy.
Status: Terminated, Estimated PCD: 2022-09-30
Product
ERDAFITINIB
Product
Irinotecan
Clinical trial
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
Status: Active (not recruiting), Estimated PCD: 2021-11-24
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-04-21
Product
Pembrolizumab/Vibostolimab
Clinical trial
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2025-09-01
Product
Avutometinib + Sotorasib
Product
Avutometinib + Sotorasib + Defactinib
Clinical trial
Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Oligo-residual Intracranial Disease After First-line Third-generation EGFR Inhibitors: a Multicenter, Randomized Clinical Trial.
Status: Recruiting, Estimated PCD: 2028-08-10
Product
EGFR-TK Inhibitor
Clinical trial
A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-02-03
Product
REGN2810
Drug
Varlilumab
Clinical trial
Clinical Investigation of Chimeric Costimulatory Converting Receptor(CCCR)-Modified NK92 Cells in Previously Treated Advanced Non-small Cell Lung Carcinoma
Status: Completed, Estimated PCD: 2020-11-30
Product
CCCR-NK92
Clinical trial
A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Status: Recruiting, Estimated PCD: 2025-04-01
Product
IMT-009
Product
Fruquintinib
Clinical trial
Phase I Multicenter Trial Combining Nivolumab, Alone or With Ipilimumab, Plus Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
Status: Terminated, Estimated PCD: 2019-07-02
Drug
nivolumab
Clinical trial
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
An Open-Label Phase I/II Study to Evaluate the Safety and prelimiBasnary Efficacy of Amivantamab and Tepotinib Combination in MET-altered Non-small Cell Lung Cancer (NSCLC)
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
Status: Completed, Estimated PCD: 2022-12-31
Product
nab-Paclitaxel
Clinical trial
A Study of LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer to Evaluate the Safety, Tolerability and Preliminary Efficacy
Status: Recruiting, Estimated PCD: 2025-07-30
Product
LK101 injection
Clinical trial
Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study
Status: Completed, Estimated PCD: 2019-01-24
Product
Bupivacaine
Product
Fentanyl
Product
Paracetamol
Product
NSAID
Product
Oral opioids
Clinical trial
A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase II Study Evaluating Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated Non-small Cell Lung Cancer (NSCLC)
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Drug
Aspirin
Drug
FOLFOXIRI
Clinical trial
A Multicenter, Open Label, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Bojungikki-tang(BJIKT)
Clinical trial
Immune Checkpoint Inhibitors and Carbon iON Radiotherapy In Solid Cancers With Stable Disease
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Immunotherapy (Pembrolizumab)
Clinical trial
Phase Ib Study to Test the Feasibility and Safety of a Personalized Vaccine in Combination With Low-dose Cyclophosphamide in Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Autologous dendritic cell vaccine loaded with personalized peptides
Clinical trial
T-cell Epitopes Associated With Impaired Peptide Processing (TEIPP)- Targeting Immunotherapy in Patients With Relapsed Advanced Non Small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2024-07-01
Product
TEIPP24
Clinical trial
A Phase 1 Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2022-02-04
Clinical trial
Neoadjuvant Sintilimab Plus Chemotherapy in EGFR-mutant Stage II-IIIB NSCLC: A Single-arm, Open-label Prospective Study
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Nab paclitaxel
Clinical trial
A Phase I/II Trial of PARP Inhibition, Radiation, and Immunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - PRIO Trial
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Paclitaxel in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial) [TOP 1705]
Status: Completed, Estimated PCD: 2023-03-12
Drug
Lurbinectedin
Clinical trial
A Prospective, Multi-center, Single-arm Exploratory Clinical Study of Envafolimab Combined With Endostar in the First-line Treatment of Driver Gene-negative Advanced Non-small Cell Lung Cancer With PD-L1 Positive Expression
Status: Recruiting, Estimated PCD: 2024-05-30
Drug
Envafolimab
Drug
Endostar
Clinical trial
A Phase II Study of Pembrolizumab Plus Platinum and Pemetrexed as First Line Therapy in Advanced Non-squamous Non-small Cell Lung Cancer Patients With EGFR Exon 21 Point Mutation and Programmed Cell Death Ligand 1 Expression
Status: Not yet recruiting, Estimated PCD: 2027-11-30
Clinical trial
Study of Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer (BRIO)
Status: Not yet recruiting, Estimated PCD: 2025-08-31
Product
Propranolol
Clinical trial
LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES
Status: Recruiting, Estimated PCD: 2026-12-28
Clinical trial
Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC With HER2 Alterations, a Phase II Study
Status: Not yet recruiting, Estimated PCD: 2024-10-01
Product
RC48+Tislelizumab+carboplatin
Product
RC48+Furmonertinib
Clinical trial
A Phase Ib Trial of PBF-1129 and Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Adenosine A2B Receptor Antagonist
Clinical trial
Administration of T Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch in Subjects With Lung Cancer
Status: Recruiting, Estimated PCD: 2025-02-15
Product
iC9.GD2.CAR.IL-15 T Infusion
Clinical trial
A Prospective, Two Cohort, Multicenter Phase II Clinical Study of Envafolimab Combined With Concurrent Chemoradiotherapy and Immune Maintenance Therapy For Limited Stage Small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2026-12-30
Clinical trial
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Fosifloxuridine
Clinical trial
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Status: Active (not recruiting), Estimated PCD: 2027-02-01
Drug
lenalidomide
Clinical trial
A Phase II Randomized Controlled Trial of TKI Alone Versus TKI and Local Consolidative Radiation Therapy in Oncogene Driver Mutated Oligo Metastatic Non Small Cell Lung Cancer Patients
Status: Recruiting, Estimated PCD: 2023-11-11
Drug
TKI
Clinical trial
A Phase 1 Study of Temozolomide in Combination With Targeted Therapy for NSCLC Patients With CNS Progression on Either Osimertinib or Lorlatinib
Status: Completed, Estimated PCD: 2022-04-25
Product
Temozolomide + Osimertinib
Product
Temozolomide + Lorlatinib
Clinical trial
A Phase 1b Neoadjuvant Trial of Sirolimus Followed by Durvalumab (MEDI4736) in Resectable Non-small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2022-11-04
Drug
rapamycin
Clinical trial
Study of Atezolizumab in Combination With Carboplatin + Paclitaxel +Bevacizumab vs With Pemetrexed + Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR(+) or ALK(+)
Status: Active (not recruiting), Estimated PCD: 2023-03-11
Product
Atezolizumab(Tecentriq)
Clinical trial
Safety and Tolerability of Bexmarilimab Plus Pembrolizumab for Patients With Advanced (Inoperable or Metastatic) Non-small Cell Lung Cancer (NSCLC)
Status: Withdrawn, Estimated PCD: 2025-12-01
Product
Bexmarilimab
Clinical trial
Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes and Its Prediction of Immune Efficacy of Patients With Non-small Cell Lung Cancer
Status: Completed, Estimated PCD: 2023-03-01
Product
Sindillimab
Clinical trial
Exploration of the Clinical Application of Almonertinib in the First-line Treatment of Patients With EGFR Mutation-positive Advanced Non-small Cell Lung Cancer With Poor Performance Status
Status: Recruiting, Estimated PCD: 2024-12-28
Drug
Almonertinib
Clinical trial
Phase II Trial of Oral Iloprost for the Precision Chemoprevention of Lung Cancer
Status: Withdrawn, Estimated PCD: 2026-12-01
Clinical trial
Nivolumab Plus Ipilimumab Plus Two Cycles of Platinum-based Chemotherapy as First Line Treatment for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC) Patients With Synchronous Brain Metastases
Status: Recruiting, Estimated PCD: 2026-03-15
Clinical trial
The Potential Risks and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer
Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Non-comparative Randomized Phase II Trial Evaluating the Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced Non-squamous NSCLC Progressing After Immunotherapy and Chemotherapy
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
The Safety and Feasibility of Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Locally Advanced Resectable Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
sintilimab
Drug
bevacizumab
Clinical trial
Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.
Status: Recruiting, Estimated PCD: 2024-02-28
Clinical trial
Engineering Gut Microbiome to Target Cancer-Immune Microenvironment in Breast and Lung Cancer
Status: Completed, Estimated PCD: 2023-03-08
Product
Probiotic
Product
Nogapendekin Alfa
Clinical trial
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-01
Product
CHS-388
Clinical trial
Efficacy and Safety Analysis of Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC，Guiding by Cerebrospinal Fluid ctDNA Detection
Status: , Estimated PCD: 2025-04-30
Clinical trial
Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Status: Recruiting, Estimated PCD: 2026-03-01
Drug
Adagrasib
Clinical trial
Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib (LUCAS)
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Product
Lazertinib/Pemetrexed/Carboplatin
Clinical trial
A Clinical Pathway for the Treatment of Multifocal Lung Adenocarcinoma Using Genome Sequencing
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Product
Multifocal Lung Adenocarcinoma
Clinical trial
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Status: Active (not recruiting), Estimated PCD: 2023-10-31
Clinical trial
Efficacy and Safety of PVT-1 Treatment in Patients With Advanced and Refractory Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Product
PVT-1
Clinical trial
Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases：A Retrospective Study
Status: Completed, Estimated PCD: 2021-09-05
Product
Immune Therapy
Clinical trial
Analyse du Profil moléculaire Des Exosomes de la Veine Pulmonaire Dans le Cancer Bronchique de Stade précoce
Status: Active (not recruiting), Estimated PCD: 2023-08-21
Product
Blood samples
Clinical trial
A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2023-02-24
Clinical trial
A Prospective, Multicenter Phase II Clinical Study of Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB Driver Gene-negative Non-small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
CAR-T Cell Targeting GPC3 for Immunotherapy of Hepatocellular Carcinoma: Phase I Clinical Trial
Status: Recruiting, Estimated PCD: 2025-08-01
Product
GPC3 and/or TGFβ targeting CAR-T cells
Clinical trial
A Phase 1 Clinical Study to Evaluate IMM2520 Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-03-10
Product
IMM2520
Clinical trial
Phase II Multi-center Study of Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in NSCLC (Non-small Cell Lung Cancer) Patients With Targetable Genetic Alterations in Their Tumor Previously Treated With Appropriate Targeted Agents With Progressive Disease
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2022-01-19
Product
ARG1-18,19,20
Clinical trial
A Prospective, Open-label, Single-arm, Phase II Trial Investigating the Efficacy and Safety of Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
Status: Recruiting, Estimated PCD: 2025-07-07
Drug
PD-1 monoclonal antibody
Clinical trial
A Study to Determine Regional Lung Function in Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Radiotherapy Using Hyperpolarized Xenon Gas MR Imaging
Status: Completed, Estimated PCD: 2020-12-31
Product
Hyperpolarized Xenon Gas
Clinical trial
Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease (Pneumonitis) Related to the Treatment of Solid Tumors With Anti-programmed-death Type 1 Receptor or Ligand Antibodies
Status: , Estimated PCD: 2024-02-01
Product
Prolonged glucocorticosteroid
Clinical trial
Phase II Study of Dose Attenuated Chemotherapy in Patients With Lung Cancer and Age > 70 and/or Comorbidities
Status: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Checkpoint Blockade Immune
Clinical trial
The Efficacy and Safety of Aumolertinib Combined Ommaya Reservoir Intrathecal Chemotherapy With Pemetrexed for Leptomeningeal Metastasis From EGFR-mutated NSCLC and Investigate the Efficacy Prognostic Value of Dynamic Changes of cfDNA
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Aumonertinib
Clinical trial
Quest for Tumour Evolution of Non-small Cell Lung Cancer in Chinese (Unicorn-Quest)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Product
Next generation sequencing
Clinical trial
Phase I/II Trial of Anti-CTLA4-NF mAb (BMS-986218) in Combination With Nivolumab and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-05-27
Product
BMS-986218
Clinical trial
A Phase I/II, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Antitumor Activity of SY-3505 Capsule in Patients With ALK-positive Advanced Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-04-26
Clinical trial
A Phase Ib/II Trial to Evaluate Safety, Tolerability and Efficacy of Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Product
LY3295668
Clinical trial
Phase II Trial Evaluating the Efficacy and Safety of Carboplatin Plus Pemetrexed in Human Immunodeficiency Virus Positive (HIV+) Patients With Stage III (Not Amenable to Radiation or Inoperable) or Stage IV Nonsquamous Non Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2016-01-01
Clinical trial
Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer: a Prospective Single-arm Study
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Prospective，Single Center, Randomized Control，Phase III Clinical Study for Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Patients With Stage ⅢB-Ⅳ NSCLC Who Failed With First-line Therapy
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
Status: Terminated, Estimated PCD: 2021-03-18
Clinical trial
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Circulating DNA to Improve Outcome of Oncology PatiEnt: A Randomized Study - COPE Study
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Liquid biopsy
Clinical trial
A Perspective Observation Phase II, Single-Arm Study Evaluating the 1st Line Efficacy and Safety of Sunvozertinib Plus Anlotinib in EGFR-Sensitive Mutations Combined With Co-Mutations Locally Advanced or Metastatic NSCLC
Status: Not yet recruiting, Estimated PCD: 2025-12-30
Product
Sunvozertinib + Anlotinib
Clinical trial
Impact of Lazertinib Dose Modification on Effectiveness and Safety in EGFR T790M-Positive Advanced Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Single-arm, Open-label, Phase I Study to Evaluate the Safety and Efficacy of CXCR5 Modified EGFR Chimeric Antigen Receptor Autologous T Cells in EGFR-positive Patients With Advanced Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-11-01
Product
CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells
Clinical trial
A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab and With Standard Chemotherapy in Patients With Advanced Lung Cancer
Status: Recruiting, Estimated PCD: 2024-09-18
Product
Recombinant humanized anti-BTLA monoclonal antibody
Clinical trial
UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients
Status: Recruiting, Estimated PCD: 2023-03-01
Clinical trial
Efficacy and Safety of Ametinib Combined With Bevacizumab in First-line Treatment of Non-oligometastatic Advanced NSCLC With EGFR-mutations.
Status: Recruiting, Estimated PCD: 2023-12-01
Product
Ametinib + Bevacizumab
Clinical trial
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
Phase I Trial of the MEK Inhibitor AZD6244 in Combination With Thoracic Radiotherapy in Non-small Cell Lung Cancer
Status: Completed, Estimated PCD: 2017-02-08
Product
AZD6244
Clinical trial
Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine: a Randomized, Double-blind, Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2025-03-09
Product
Lidocaine
Clinical trial
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-04-10
Product
BMS-986340
Clinical trial
An Open-label, Multicenter, First-in-human Dose-escalation and Cohort Expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of IMM2902 in the Treatment of HER2-expressing Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-10-01
Product
IMM2902
Clinical trial
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial
Status: Recruiting, Estimated PCD: 2027-12-01
Product
Sevoflurane
Clinical trial
A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
The Effects of an Oncology Tailored Nutritional Intervention on the Bioavailability and Immune-activity of PD-1 Immune Checkpoint Inhibitors in Patients With Lung Cancer
Status: Recruiting, Estimated PCD: 2023-07-06
Clinical trial
A Prospective, Single-arm, Phase II Trial of Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Advanced Non-squamous Non-small Cell Lung Cancer After First-line Immunotherapy Progression
Status: Recruiting, Estimated PCD: 2023-06-01
Clinical trial
Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease - An Open Label Randomized Phase III Trial Comparing Up-front Radiation in Oligometastatic Non-small Cell Lung Cancer (NSCLC) and Systemic Treatment With Systemic Treatment Alone
Status: Not yet recruiting, Estimated PCD: 2027-12-01
Product
Standard systemic therapy
Clinical trial
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment With Osimertinib (AZD9291, Tagrisso)
Status: Completed, Estimated PCD: 2022-05-25
Clinical trial
Anlotinib With or Without Immune Checkpoint Inhibitors in Standard Chemo-immunotherapy Failed Advanced Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2028-03-24
Product
Anlotinib
Clinical trial
A Ph1b Study of Osimertinib + Alisertib or Sapanisertib for Osimertinib-Resistant EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) (Crossover Study)
Status: Completed, Estimated PCD: 2023-07-27
Product
Alisertib
Clinical trial
Phase II Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases
Status: Not yet recruiting, Estimated PCD: 2024-06-01
Drug
Tocilizumab
Clinical trial
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction
Status: Active (not recruiting), Estimated PCD: 2018-11-29
Product
Romidepsin
Clinical trial
Evaluation of Blood Tumor Mutation Burden (TMB) for Improved Efficacy of Atezolizumab in 2nd Line Non-small Cell Lung Cancer (NSCLC) [BUDDY]
Status: Completed, Estimated PCD: 2021-12-31
Clinical trial
A Pilot Trial of Ipilimumab-Nivolumab in Local-Regionally Advanced Non Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
New Method of Treatment for Thoracoscopy or Bronchoscopy by Suspension of Fine Powder of Talcum and Afatinib is Used in Patients With Positive Mutation of EGFR in Non-Small Cell Lung Carcinoma (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2023-02-21
Product
Talcum powder
Clinical trial
Postoperative Pain Management on Patients Undergoing Video-assisted Thoracoscopic (VATS) Lung Tumor Resection: a Prospective Cohort Study
Status: Not yet recruiting, Estimated PCD: 2026-03-02
Product
Dinalbuphine
Product
Analgesic injectables
Product
Enteral analgesics
Clinical trial
Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer
Status: Completed, Estimated PCD: 2023-01-01
Product
Concurrent Chemotherapy
Product
Consolidation Immunotherapy
Clinical trial
A Randomized Trial of Consolidative Immunotherapy With vs Without Thoracic Radiotherapy and / or Stereotactic Body Radiation Therapy (SBRT) After First-Line Systemic Therapy for Metastatic NSCLC
Status: Active (not recruiting), Estimated PCD: 2027-07-31
Clinical trial
A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-12-01
Product
XmAb®808
Clinical trial
A Prospective, Single-arm Study of Adebrelimab in Combination With Paclitaxel for Injection (Albumin Bound) and Platinum Chemotherapy as Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) Harboring Driver Gene Mutations
Status: Not yet recruiting, Estimated PCD: 2026-04-15
Clinical trial
A Phase 0 Study of CIMAvax-EGF Vaccine in Patients Who Are at High Risk for Lung Cancer and Lung Cancer Survivors at Risk for Recurrence
Status: Recruiting, Estimated PCD: 2024-11-22
Clinical trial
A Prospective Phase II Controlled Study to Evaluate the Impact of Thymosin Alpha 1 on the Completion Rate of Consolidation Immunotherapy After Radical Radiochemotherapy for Locally Advanced Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Induction Chemo-Immunotherapy
Product
Concurrent chemotherapy
Product
Immunotheapy
Product
Thymosin Alpha1
Clinical trial
A Phase I Trial of Intratumoral Administration of CCL21-Gene Modified Dendritic Cell (Ad-CCL21-DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC
Status: Active (not recruiting), Estimated PCD: 2024-01-11
Product
Autologous Dendritic Cell-Adenovirus CCL21 Vaccine
Clinical trial
Single-Arm, Phase II of Immunotherapy With Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Platinum Based Chemotherapy (First-line of Systemic Treatment) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After EGFR-TKI Failure
Status: Recruiting, Estimated PCD: 2026-05-01
Product
Pemetrexed + Cisplatin or Carboplatin
Clinical trial
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Status: Active (not recruiting), Estimated PCD: 2022-01-01
Product
Rucaparib
Clinical trial
Neoadjuvant Almonertinib Followed by Adebrelimab-based Chemo-immunotherapy in II-IIIB EGFR-mutant Non-small Cell Lung Cancer, a Single Arm, Phase II Study
Status: Recruiting, Estimated PCD: 2026-03-01
Product
almonertinib
Clinical trial
Comprehensive Stereotactic Body Radiotherapy (SBRT) to All Sites of Oligometastatic Non-small Cell Lung Cancer (NSCLC) Combined With Durvalumab (MEDI4736) and Tremelimumab Dual Immune Checkpoint Inhibition.
Status: Terminated, Estimated PCD: 2020-07-01
Clinical trial
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung Cancer
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Systemic Therapy
Clinical trial
A Single-center, Open Label, Exploratory Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of WTX212A Injection Combined With PD -1/PD-L1 Monoclonal Antibody in Patients With Advanced Lung Cancer
Status: Recruiting, Estimated PCD: 2024-10-30
Product
WTX212A
Product
PD-1/PD-L1 monoclonal antibody
Clinical trial
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
Status: Recruiting, Estimated PCD: 2034-02-21
Clinical trial
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Status: Completed, Estimated PCD: 2018-06-05
Drug
pembrolizumab
Clinical trial
UCLA L-08: A Phase Ib/II Study of Combined HER Inhibition Adding Necitumumab and Trastuzumab to Osimertinib in Patients With Refractory EGFR-Mutated Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-02
Clinical trial
MELROSE: Phase 2 Study Evaluating MEchanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtinib Until and Beyond Radiological Progression : the MELROSE Trial
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
TAGRISSO
Product
Tumor biopsies
Product
ctDNA analysis
Clinical trial
A Single Arm, Exploratory Clinical Study on the Prevention of Bone Marrow Suppression Caused by Platinum Containing Chemotherapy in Advanced Non-small Cell Lung Cancer With Trilaciclib
Status: Not yet recruiting, Estimated PCD: 2025-04-30
Drug
Trilaciclib
Clinical trial
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
A Randomized, Controlled, Multicenter Phase II Clinical Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
Status: Recruiting, Estimated PCD: 2027-05-19
Product
Platinum based chemotherapy
Clinical trial
A Single Arm Trial of Adjuvant Pembrolizumab in Patients With Limited Stage Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2028-05-31
Drug
TQB2450
Clinical trial
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Atezolizumab + BDB001 + RT
Product
Atezolizumab + BDB001
Product
Association atezolizumab + BDB001
Clinical trial
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Product
LY4052031
Clinical trial
Adebrelimab Plus Albumin-bound Paclitaxel, Carboplatin and Recaticimab Perioperative Treatment for Resectable NSCLC, a Phase II Clinical Study
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Negative Driver Genes and Failed Immunotherapy
Status: Recruiting, Estimated PCD: 2026-12-30
Product
Cadonilimab
Clinical trial
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer: a Single-arm, Prospective, Exploratory Clinical Study
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
An Open, Single-armed, Phase Ib Study to Evaluate the Safety and Efficacy Using Autologous TIL in Patients With Non-Small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Product
Autologous Tumor Infiltrating Lymphocytes
Clinical trial
A Prospective, Multicenter, Phase II Study Evaluating the Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Drug
BL-B01D1
Product
PD-1 Monoclonal Antibody
Clinical trial
Multicenter, Randomized, Phase Ib/IIb Study to Evaluate the Efficacy and Tolerability of Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone, in Patients With EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
Status: Completed, Estimated PCD: 2016-07-01
Clinical trial
A Dose Escalation and Expansion Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-1942 in Patients With Advanced Solid Tumor and/or Relapsed/Refractory Hematologic Malignancies
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
TGRX-1942
Clinical trial
A Pilot Study of 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
Status: Recruiting, Estimated PCD: 2025-12-31
Product
68Ga-FAPI-RGD
Drug
18F-FDG
Product
68Ga-FAPI
Product
68Ga-RGD